[go: up one dir, main page]

TWI331605B - A process for the preparation of racemic citalopram diol and/or s- or r-citalopram diols and the use of such diols for the preparation of racemic citalopram, r-citalopram and/or s-citalopram - Google Patents

A process for the preparation of racemic citalopram diol and/or s- or r-citalopram diols and the use of such diols for the preparation of racemic citalopram, r-citalopram and/or s-citalopram Download PDF

Info

Publication number
TWI331605B
TWI331605B TW092135925A TW92135925A TWI331605B TW I331605 B TWI331605 B TW I331605B TW 092135925 A TW092135925 A TW 092135925A TW 92135925 A TW92135925 A TW 92135925A TW I331605 B TWI331605 B TW I331605B
Authority
TW
Taiwan
Prior art keywords
diol
acid addition
addition salt
free base
residue
Prior art date
Application number
TW092135925A
Other languages
Chinese (zh)
Other versions
TW200512202A (en
Inventor
Hans Petersen
Robert Dancer
Brian Christiansen
Rikke Eva Humble
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of TW200512202A publication Critical patent/TW200512202A/en
Application granted granted Critical
Publication of TWI331605B publication Critical patent/TWI331605B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00Preparation of carboxylic acid nitriles
    • C07C253/32Separation; Purification; Stabilisation; Use of additives
    • C07C253/34Separation; Purification
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87Benzo [c] furans; Hydrogenated benzo [c] furans

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

1331605 將s-二元醇在乙腈中的溶液(5〇〇毫升約5〇 55%w/w ,S : R比例95.72 : 4·28)在室溫下攪拌冷卻到_14。C。於 2。C溫度下逐滴加入幾乎·消旋性二元醇(s : r比例約6〇 :40)以接種該混合物。力16 +時之後,過渡該混合物 並將濾餅乾燥。分析濾餅顯示出s : R比例為57 97 42.03。分析母液顯示出s : R比例為% 〇65 : ^们5。 實施例3 經由將消旋二元醇游離鹼沉澱以純化s•二元醇 將s-二元醇在乙腈中的溶液(5〇0毫升約5〇55%w/w φ ,3:尺比例95.72:4.28)在室溫下以1。(:/小時之速率攪 拌冷卻到-10° C。於5。c溫度下逐滴加入幾乎消旋性二 兀醇(S : R比例約6〇 : 4〇)以接種該混合物。於·丨〇。c下 4〇小時之後,過濾該混合物,並將濾餅乾燥。分析濾餅顯 示出S : R比例為59.19 : 4〇 81。分析母液顯示出s : R比 例為 98.52 : 1,48。 實施例4 經由將消旋二元醇沉澱成鹽酸鹽以純化s_二元醇 · 通用方法: 將R-和S-二元醇的混合物(如下面的表中所定義者)(j 克)溶解在曱苯(10毫升)中。加入鹽酸水溶液(1 〇當量,濃 度為如下面的表中所界定者),且加入固體氣化鈉(足夠量 使得NaCl在水中的濃度約為1或2 M;參看下面的表)。 將該混合物攪拌整夜,且過濾。將剩餘物乾燥而得雜含某 些S-二元醇鹽酸鹽的消旋二元醇鹽酸鹽晶體。使用氨水溶 29 1331605 液將母液鹼化到pH > 9,且分離屮田贫麻 — 且刀離出甲本層。用甲苯將水層 再萃取一次,並將合併甲芏苴& + 本卒取液以硫酸鎂脫水及減壓蒸 發而得内雜少量R-二元醇的主要 _ ㈣主要S-一兀醇。參看表中所列 坪情。物質的回收率幾乎為全吾去 „. 卞马王$者,具有預期的在個別樣 品之間的重量分配。 1^1 沉救之前 異構物H L合物 HC1水溶液 濃度 (M) NaCl水溶 液濃度 (M) 沉 ;儿搬物(R-和S*·二 元醇的混合物) 救之後 驗化、分離和蒸發之後 為油狀物(富含S-鏡像異 槿物Ί S% R% S% R% S% 0¾ 82.3 17.7 1.0 1.0 58.4 41.6 99.4 IV/0 0 β 82.3 17.7 2.0 1.0 49.7 50.3 97.7 2 3 82.3 17.7 1.0 2.0 81.3 「18.7 86.2 13.8 82.3 17.7 2.0 2.0 60.1 39.9 99.7 0.3 實施例5 經由將消旋二元醇沉澱成對-甲苯磺酸鹽、曱烷磺酸鹽 或醋酸鹽以純化S -二元醇 通用方法: β 將R-和S-二元醇的混合物(如下面的表中所定義者)(ι 克)溶解在甲苯或乙醚(1〇毫升;如下面的表中所述者)中。 加入NaCl水溶液(丨μ,3毫升)。以液體形式加入純酸(如 下面的表中所定義者)。將該混合物攪拌整夜,且過濾或傾 析°將剩餘物乾燥而得一油狀物或固體。使用氨水溶液將 母液鹼化到pH > 9,且分離出曱笨層或乙醚層。用曱苯或 乙醚將水層再萃取一次,並將合併有機萃取液以硫酸鎂脫 30 !3316〇5 水及減壓蒸發而得主要為一固體 ^ 油狀物。表丟矣击 列詳情。物質的回收率幾乎為全量 M a ^ ^ V 者具有預期的在個別 樣〇〇之間的重置分配。 沉戰之俞 -----— 異楢物混会物 溶劑 酸 (當量) 沉激物(R-和 的混合物) 殿之猞 0¾ DW: 二元醇 鹼化、分離和蒸發之後 為油狀物(富含S-鏡像異 構物) 〇/〇 82.3 two 17.7 甲苯 MsOH (1) S% 64.厂 35 fi S% R% 94.3 5.7 82.3 17.7 甲苯 MsOH (2) 48.2 Cl A 82.3 17.7 乙醚 MsOH (1) 62.9 i)1.8 37 1 90.0 10.0 82.3 17.7 乙醚 MsOH (2) 55.1 44.9 91.0 89 3 9.0 82.3 17.7 曱笨 AcOH (1) AcOH (2) 71.3 65. 9 — 34.1 96.2 94 8 10. 7 3.8— 82.3 17.7 曱笨 C 〇 82.3 17.7 乙醚 AcOH (1) 65.0 35.0 91 6 p A 82.3 | 17.7 乙醚 AcOH (2) 65.7 87.2 〇. 4 12.8 實施例6 經由在不含水之下沉澱消旋二元醇鹽以純化s_二元醇 通用方法: 將R-和S-二元醇的混合物(如下面的表中所定義者 克)溶解在曱苯或乙醚(10毫升;如下面的表中所述者)中。 以固體形式加入純酸(如下面的表中所定義者)。將該混合 物攪拌整夜,且過濾或傾析。將剩餘物乾燥而得一油狀物 或固體。於母液_加入水,並使用氨水溶液將母液鹼化到 pH > 9,且分離出甲苯層或乙醚層。用曱苯或乙醚將水層 再萃取一次’並將合併有機萃取液以硫酸鎂脫水及減壓蒸 31 丄丄ου:) ,而付主要為-固體或-油狀物。參看表中所列詳情。物 質的回收率幾乎為全量者,具有預期的在個別樣品之間的 重量分配。 __ 沉 澱之 —-- 溶劑 前 _____沉澱之後 屁兮物 酸 (當量) 沉澱物(R-和s-二元醇的 混合物) 驗化、分離和蒸發之後 為油狀物(富含S-鏡像異 S% R% S% R% S% m J_2.3 17.7 甲笨 TsOH(0.4) 54.9 45.1 90.9 8 1 —82.j 17.7 _乙醚 TsOH(0.4) 57.4 42.6 98.1 7 9 82.3 17.7 曱苯 (C02H)2 (0.2) 78.4 21.6 93 7 似.3 17.7 曱苯 _)2 (0.4) 72.1 27.8 99.97 0 03 82.3 17.7 曱苯 (C02H)2 (1) 82.2 17.8 99.6 0 4 82.3 17.7 乙醚 (C02H)2 (0.2) 58.0 42.0 97.7 2 3 _82.3 17.7 乙醚 (_2 (0.4) 55.4 44.6 98.4 16 82.3 17.7 乙醚 _)2 a) 72.0 28.0 99.5 0.5 實施例7 經由在不含水之下使用多種溶劑沉澱消旋二元醇鹽以 純化S-二元醇 · 通用方法: 將R-和S-二元醇的混合物(如下面的表中所定義者)(】 克)溶解在溶劑(10毫升;如下面的表中所述者)中β以固體 形式加入純酸(如下面的表中所定義者)。將該混合物攪掉 整夜,且於有形成沉澱物之時予以過濾或傾析。於已經形 成沉澱物之情況中,將剩餘物乾燥而得一油狀物或固體。 將母液蒸發’並將剩餘物溶取在乙醚和水的混合物中。使 32 ^31605 用氨水溶液將母液驗化到pH > 9,且分離出乙㈣。用乙 驗將水層再萃取—次,並將合併乙料取液以硫酸鎮脫水 j減壓蒸發而得主要為一固體或—油狀物。參看表中所列 詳情。物質的回收率幾手為全景 千戍卞局生里者,具有預期的在個別樣 品之間的重量分配。 98.2 1.8 98.5 1.5 99.6 0.4 ~~1331605 A solution of s-diol in acetonitrile (5 liters of about 5 〇 55% w/w, S:R ratio 95.72: 4·28) was stirred and cooled to _14 at room temperature. C. At 2. An almost racemic diol (s:r ratio of about 6 Torr: 40) was added dropwise at C temperature to inoculate the mixture. After a force of 16 +, the mixture was transitioned and the filter cake was dried. The analytical filter cake showed an s : R ratio of 57 97 42.03. The analysis of the mother liquor showed an s : R ratio of % 〇 65 : ^ 5 . Example 3 A solution of s-diol in acetonitrile (5 〇 0 ml of about 5 〇 55% w/w φ , 3: 尺 ratio) by precipitating a racemic diol free base to purify s• diol 95.72: 4.28) 1 at room temperature. (:/hour rate, stir and cool to -10 ° C. Add almost racemic didecyl alcohol (S: R ratio about 6 〇: 4 〇) at a temperature of 5. C to inoculate the mixture. After 4 hours, the mixture was filtered and the filter cake was dried. The analysis cake showed an S:R ratio of 59.19: 4 〇 81. The analysis of the mother liquor showed a ratio of s:R of 98.52: 1,48. Example 4 Purification of s-diol by precipitation of a racemic glycol to a hydrochloride salt. General method: Mixture of R- and S-diols (as defined in the table below) (j g Dissolved in toluene (10 ml). Add aqueous hydrochloric acid (1 〇 equivalent, as defined in the table below), and add solid sodium sulphate (sufficient amount to make NaCl concentration in water is about 1 or 2 M; see table below. The mixture was stirred overnight and filtered. The residue was dried to give racemic diol salt crystals containing some of the S-diol salt. Water-soluble 29 1331605 liquid alkalized the mother liquor to pH > 9, and separated from the field, and the knife leaves the layer. The layer is watered with toluene. The extract is again extracted, and the combined formazan & + stroke liquid is dehydrated with magnesium sulfate and evaporated under reduced pressure to obtain the main _ (four) main S-monosterol of a small amount of R-diol. See the table The recovery rate of the substance is almost the same as that of the whole person. 卞. 卞马王$, has the expected weight distribution between individual samples. 1^1 The concentration of the HCl compound HCl solution before the rescue (M ) NaCl aqueous solution concentration (M) Shen; children's moving material (mixture of R- and S*·diol) After the rescue, separation and evaporation, it is an oil (rich in S-mirror isotopes Ί S%) R% S% R% S% 03⁄4 82.3 17.7 1.0 1.0 58.4 41.6 99.4 IV/0 0 β 82.3 17.7 2.0 1.0 49.7 50.3 97.7 2 3 82.3 17.7 1.0 2.0 81.3 "18.7 86.2 13.8 82.3 17.7 2.0 2.0 60.1 39.9 99.7 0.3 Example 5 Purification of S-diol by precipitation of the racemic glycol to p-toluenesulfonate, decanesulfonate or acetate General method: β A mixture of R- and S-diols (as below) (defined in the table) (ι) is dissolved in toluene or ether (1 〇 ml; as described in the table below). Aqueous NaCl solution (丨μ, 3 ml). Add pure acid (as defined in the table below) in liquid form. Stir the mixture overnight and filter or decante to dry the residue to give an oil. Or a solid. The mother liquor is alkalized to pH > 9, using an aqueous ammonia solution, and a layer of ruthenium or diethyl ether is isolated. The aqueous layer was extracted once more with benzene or diethyl ether. The combined organic extracts were taken from <RTI ID=0.0>> Table loses the list of details. The recovery of the substance is almost the full amount of M a ^ ^ V with the expected reset distribution between individual samples.战战之俞------ isophthalate mixture solvent acid (equivalent) stimulator (R- and mixture) 殿之猞03⁄4 DW: diol alkalization, separation and evaporation after oily (Enriched S-mirroromer) 〇/〇82.3 two 17.7 Toluene MsOH (1) S% 64. Plant 35 fi S% R% 94.3 5.7 82.3 17.7 Toluene MsOH (2) 48.2 Cl A 82.3 17.7 Ethyl ether MsOH ( 1) 62.9 i) 1.8 37 1 90.0 10.0 82.3 17.7 Ethyl ether MsOH (2) 55.1 44.9 91.0 89 3 9.0 82.3 17.7 Ac Ac AcOH (1) AcOH (2) 71.3 65. 9 — 34.1 96.2 94 8 10. 7 3.8— 82.3 17.7 曱 C C 〇 82.3 17.7 Ethyl ether AcOH (1) 65.0 35.0 91 6 p A 82.3 | 17.7 Ethyl ether AcOH (2) 65.7 87.2 〇. 4 12.8 Example 6 Purification by precipitation of the racemic diol salt without water General procedure for s_diols: A mixture of R- and S-diols (as defined in the table below) is dissolved in toluene or diethyl ether (10 ml; as described in the table below) . The pure acid is added as a solid (as defined in the table below). The mixture was stirred overnight and filtered or decanted. The residue is dried to give an oil or a solid. Water was added to the mother liquor _, and the mother liquor was alkalized to pH > 9, using an aqueous ammonia solution, and a toluene layer or a diethyl ether layer was separated. The aqueous layer is re-extracted once with terpene or diethyl ether. The combined organic extracts are dehydrated with magnesium sulfate and evaporated under reduced pressure of 31 丄丄ου:), which is mainly a solid or an oil. See the details listed in the table. The recovery of the substance is almost full and has the expected weight distribution between individual samples. __ Precipitation - pre-solvent _____ after precipitation, fart acid (equivalent) Precipitate (mixture of R- and s-diol) After oiling, separation and evaporation, it is oily (rich in S- Mirroring different S% R% S% R% S% m J_2.3 17.7 A Stupid TsOH (0.4) 54.9 45.1 90.9 8 1 —82.j 17.7 _Ethyl ether TsOH (0.4) 57.4 42.6 98.1 7 9 82.3 17.7 Benzene (C02H) ) 2 (0.2) 78.4 21.6 93 7 Like .3 17.7 Benzene _) 2 (0.4) 72.1 27.8 99.97 0 03 82.3 17.7 Benzene (C02H) 2 (1) 82.2 17.8 99.6 0 4 82.3 17.7 Ether (C02H) 2 ( 0.2) 58.0 42.0 97.7 2 3 _82.3 17.7 Ethyl ether (_2 (0.4) 55.4 44.6 98.4 16 82.3 17.7 diethyl ether _) 2 a) 72.0 28.0 99.5 0.5 Example 7 Precipitation binary via two kinds of solvents without water Alkoxide to purify S-diols. General method: Mix a mixture of R- and S-diols (as defined in the table below) (g) in a solvent (10 ml; as shown in the table below) In the above, β is added as a solid acid in a solid form (as defined in the table below). The mixture was stirred overnight and filtered or decanted as it formed a precipitate. In the case where a precipitate has been formed, the residue is dried to obtain an oil or a solid. The mother liquor was evaporated' and the residue was taken up in a mixture of diethyl ether and water. The mother liquor was assayed to pH > 9 with aqueous ammonia solution at 32 ^ 31605 and B (tetra) was isolated. The aqueous layer was re-extracted by means of the test, and the combined liquids were extracted by dehydration of sulfuric acid and reduced under reduced pressure to obtain a solid or oily substance. See the details listed in the table. The recovery rate of the material is a few hands. The Millennium Bureau has the expected weight distribution between individual samples. 98.2 1.8 98.5 1.5 99.6 0.4 ~~

實施例8 經由沉澱消旋二元醇草酸鹽以純化s_ _ _ s^· 通用方法: 的表中所定義者)(1 水溶液(1 Μ,3毫 將R-和S-二元醇的混合物(如下面 克)溶解在甲苯(10毫升)中》加入NaC1 33 Ϊ331605 升)並以固體形式加入純草酸(如下面的表中所定義者)。將 該混合物攪拌整夜,且於有形成沉澱物之時予以過瀘或傾 析。於已經形成沉澱物之情況中,將剩餘物乾燥而得一油 狀物或固體。使用氨水溶液將母液鹼化到pH > 9,且分離 出曱笨層。用甲苯將水層再萃取一次,並將合併甲苯萃取 液以硫酸鎂脫水及減壓蒸發而得主要為一固體或一油狀物 。參看表中所列詳情。物質的回收率幾乎為全量者,具有 預期的在個別樣品之間的重量分配。 沉澱之 —前 ----- 沉澱夕轉 異構物混合物 草酸 (當量) 沉澱物(R-和S-二元醇的 混合物) 驗化、分離和蒸發之後為油狀 鏡像異構物) S% R% S% R% S% R% 82.3 17.7 0.2 51.8 48.2 98.5 15 82.3 17.7 0.4 62.6 37.4 99.8 0 2 82.3 17.7 1.0 58.6 41.4 97.0 3.0 82.3 17.7 2.0 56.7 43.3 92.7 7.3 實施例9 經由在水中沉澱消旋二元醇鹽酸鹽以純化s二元醇 通用方法: 將R-和S-二兀醇的混合物(如下面的表中所定義者 克)與HC1水溶液(1當量;參看表中所示濃度)授摔。將該 混合物攪拌整夜,並加入足量NaCl(固體形式)使得NaC1 的濃度為! Μ。過據該混合物而得—固體。於母液中加入 水和乙謎,使用氨水溶液驗化到ρΗ > 9,且分離出乙驗層 。用乙醚將水層再萃取一次’並將合併乙醚萃取液以硫酸 34 1331605 或一油狀物。參看表 量者,具有預期的在 钱脫水及減壓蒸發而得主要為一固體 中所列詳情。物質的回收率幾乎為全 個別樣品之間的重量分配。 沉澱之前 ---- —----- HC1濃度 (M) ——— 彳衫 井俯奶 况戮物(R-和S-二元醇 的混合物) 鹼化、分離和蒸發之後為油 狀物(富含S-鏡像異構物) S% R% S% R% S% D叱 82.3 17.7 1 59.4 40.6 99.2 IVD π R 82.3 17.7 2 63.7 36.3 99.3 U. 〇 0.7 " :--1 實施例1 〇 左由在水中優先溶解消旋s_二元醇鹽酸鹽以純化二 元醇 通用方法: 將R-和S-二元醇鹽酸鹽的混合物(17 7: 82 3; 5.5克) 與NaC1水溶液0 M’ 12毫升)㈣。將該混合物搜拌整夜 ’並過濾該混合物而得-固胃。於母液中加入水和乙醚, 使用氨水溶液鹼化到pH > 9,且分離出乙驗層。用乙趟將 =層再萃取一次,並將合併乙醚萃取液以硫酸鎂脫水及減 壓蒸發而得主要為一固體或一油狀物。過濾所得剩餘物含 有比例為1.0: 99.0 @ R•二元醇和s二元醇。將濾液收拾 處理後所得產物含有比例為38 8: 61 2的R二元醇和s_ 一兀醇。物質的回收率幾乎為全量者,具有預期的在個別 樣品之間的重量分配。 35 7月V曰修(吏)正替换頁 公告 卜本 發明專利說明當 (本說明書格式、順序及粗體字,請勿任意更動,※記號部分請勿填寫) ※申請案Sfe :Example 8 Desalination of a glycol oxalate via precipitation to purify s_ _ _ s ^ · General method: as defined in the table) (1 aqueous solution (1 Μ, 3 mM R- and S-diol) The mixture (eg gram below) was dissolved in toluene (10 mL) "NaC1 33 Ϊ 331,605 liters) and pure oxalic acid (as defined in the table below) was added as a solid. The mixture was stirred overnight and formed The precipitate is subjected to hydrazine or decantation. In the case where a precipitate has formed, the residue is dried to obtain an oil or a solid. The mother liquor is alkalized to pH > The layer is re-extracted once with toluene, and the combined toluene extract is dehydrated with magnesium sulfate and evaporated under reduced pressure to give a crude solid or an oil. See the table for details. For the full amount, there is expected weight distribution between individual samples. Precipitation-pre-----precipitate mixture of oxalic acid (equivalent) precipitate (mixture of R- and S-diol) Oily mirroring after verification, separation and evaporation S) R% S% R% S% R% 82.3 17.7 0.2 51.8 48.2 98.5 15 82.3 17.7 0.4 62.6 37.4 99.8 0 2 82.3 17.7 1.0 58.6 41.4 97.0 3.0 82.3 17.7 2.0 56.7 43.3 92.7 7.3 Example 9 by precipitation in water General method for the purification of s-diols by racemic diols: a mixture of R- and S-dioxanol (as defined in the table below) with an aqueous solution of HCl (1 equivalent; see table Indicate the concentration). The mixture was stirred overnight and a sufficient amount of NaCl (solid form) was added to give a NaC1 concentration! Hey. According to the mixture, a solid is obtained. Water and a puzzle were added to the mother liquor, and an aqueous ammonia solution was used to test to ρΗ > 9, and the test layer was separated. The aqueous layer was re-extracted once with diethyl ether. The combined ether extracts were either sulphuric acid 34 1331605 or an oil. Refer to the table, with the expected details of the main solids in the dehydration and evaporation under reduced pressure. The recovery of the substance is almost the weight distribution between all individual samples. Before Precipitation---------- HC1 Concentration (M) ——— 彳 井 俯 俯 ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( (rich in S-mirror isomer) S% R% S% R% S% D叱82.3 17.7 1 59.4 40.6 99.2 IVD π R 82.3 17.7 2 63.7 36.3 99.3 U. 〇0.7 " :--1 Example 1 〇 Left by purifying the s-diol hydrochloride in water to purify the diol. General procedure: Mixture of R- and S-diol hydrochloride (17 7: 82 3; 5.5 g) With aqueous solution of NaC1 0 M' 12 ml) (d). The mixture was sifted overnight and filtered to obtain a solid stomach. Water and diethyl ether were added to the mother liquor, and alkalized to pH > 9, using an aqueous ammonia solution, and the test layer was separated. The layer was re-extracted once with acetonitrile, and the combined ether extracts were dried over magnesium sulfate and evaporated under reduced pressure to give a crude solid or oil. The residue obtained by filtration contained a ratio of 1.0: 99.0 @ R•diol and s glycol. The product obtained after the filtrate was collected and processed contained R diol and s- sterol in a ratio of 38 8:61 2 . The recovery of the substance is almost full and has the expected weight distribution between individual samples. 35 July V曰修(吏) is replacing page Announcement Buben Patent description of the invention (When the format, order and bold text of this manual are used, please do not change it arbitrarily, please do not fill in the ※ part) ※Application Sfe:

※申請日期:p兹1 PC分類:cc;?·^ 9 壹、發明名稱:(中文/英文) 44,K※Application date: p 1 PC classification: cc;?·^ 9 壹, invention name: (Chinese / English) 44, K

製備,旋西普蘭(cital〇pram)二元醇及/或8_或R_西普蘭二元 和此等二元醇用於製備消旋西普蘭,R-西普蘭及/或S-西普蘭的用途 A process for the preparation of racemic citalopram diol and/or S- or R-citalopram diols and the use of such diols for the preparation of racemic citalopram, R-citalopram and/or S-citalopram 貳、申請人:(共1人) 姓名或名稱:(中文/英文)Preparation, cital 〇pram diol and/or 8_ or R_ cypland binary and these diols for the preparation of racemate, R-Sipran and/or S-Sipland A process for the preparation of racemic citalopram diol and/or S- or R-citalopram diols and the use of such diols for the preparation of racemic citalopram, R-citalopram and/or S-citalopram 贰, applicant: (total 1 person) Name or name: (Chinese / English)

Η·朗德貝克公司/ H. LUNDBECKA/S 代表人:(中文/英文)(簽章)Η·Lundbeck Company / H. LUNDBECKA/S Representative: (Chinese / English) (signature)

拉爾斯凱傑朗卡爾德/ KJERRUMGAARD,LARS 住居所或營業所地址:(中文/英文)Lars Kejlang Calder / KJERRUMGAARD, LARS residence or establishment address: (Chinese / English)

丹麥’ DK-2500法比-哥本哈根,奥堤里雅維吉9號 Ottiliavej 9, DK-2500 Valby-Copenhagen, DENMARKDenmark ' DK-2500 Fabi - Copenhagen, Otili Yavi 9 9 Ottiliavej 9, DK-2500 Valby-Copenhagen, DENMARK

國籍:(中文/英文) 丹麥 / DENMARK 參、發明人:(共4人) i姓名:(中文/英文)Nationality: (Chinese / English) Denmark / DENMARK Participation, inventor: (4 in total) i Name: (Chinese / English)

漢斯彼德森/ PETERSEN,HANS 住居所地址:(中文/英文) 丹麥DK-2720凡洛斯市,顧爾達格街u號 Guldagervej 11, DK-2720 Vanl0se, Denmark 國籍:(中文/英文) 丹麥 / Denmark 1331605 狄、發明說明: 【發明所屬之技術領域】 本發明係關於消旋西普蘭(citalopram)二元醇及S-或 R西普蘭—元醇之製備方法’包括將化合物R—和西普蘭 二元醇(R-和S_4-[4-(二曱胺基)_卜(4,_氟苯基;羥基丁基 ]3-(沒基曱基)-苯腈)的起始非消旋性混合物分離成為一消 旋西普蘭二元醇的部份與一富含s_二元醇或R_二元醇的部 伤本發明也有關此4經分離出的西普蘭二元醇用來形成 相應的消;5疋性西普蘭及/或S _或R-西普蘭以期包括在一醫 藥組合物内之用途。 【先前技術】 西普蘭為一種熟知的抗抑鬱藥物,其至今在市場上行 銷已有多年且具有下面的結構··Hans Peterson / PETERSEN, HANS Residence Address: (Chinese / English) Danish DK-2720 Fanlos City, Gurdag Street u Guldagervej 11, DK-2720 Vanl0se, Denmark Nationality: (Chinese / English) Denmark / Denmark 1331605 Di, invention description: [Technical field to which the invention pertains] The present invention relates to a method for preparing a citalopram diol and an S- or R celand-alcohol, including a compound R- and a Primal diol (R- and S_4-[4-(didecylamino)-bu (4,-fluorophenyl; hydroxybutyl]3-(indolyl)-benzonitrile) The separation of the rotatory mixture into a fraction of a racemic cedar diol and a s-diol or R-diol-rich portion of the invention is also related to the separation of the cedar diol from the 4 To form a corresponding elimination; 5 sputum sipram and / or S _ or R - siplan in order to include the use in a pharmaceutical composition. [Prior Art] cedar is a well-known antidepressant drug, which is still in the market Upmarketing for many years and has the following structure··

西普蘭可以經由如美國專利第4,650,884號中所述者 將4-[M二曱胺基)小(4,_氣苯基)小經基丁基]_3_(芦 基)苯腈予以環閉合而製備成。產物西普蘭為R-和S二像 異構物之消旋混合物。 另外’西普蘭的 (escitalopram))為一種有 s_鏡像異構物(依西普蘭 用的選擇性血清素再攝取抑制劑 1331605 (SeIective serotonin reuptake inhibitor) (SSRI)型抗抑鬱藥 。依西普蘭可以經由如EP B1 347 066中所述者將S-4-[4-( 二甲胺基)-1-(4,-氟苯基羥基丁基]_3_(羥基f基)_苯腈 (S-二元醇)於保留構型之下予以環閉合而製備成。於產物 依西普蘭中R-西普蘭相對於s_西普蘭的量必須小於3%。 再者,於WO03000672中述及一種從含有超過5〇%r_ 二元醇的R-和S-二元醇的混合物製備含有超過5〇%s_鏡像 異構物的R-和S-西普蘭的混合物之方法。The cisplatin can be ring-closed by 4-[M-diamine-amino)succinyl (4,- phenylphenyl) hydrazino][3](rutyl)benzonitrile as described in U.S. Patent No. 4,650,884. Prepared as. The product cedar is a racemic mixture of the R- and S di-isomers. In addition, 'escitalopram' is an anti-depressant with s_mirror isomer (Sexiective serotonin reuptake inhibitor (SSRI) type). S-4-[4-(dimethylamino)-1-(4,-fluorophenylhydroxybutyl]_3_(hydroxyf-yl)-benzonitrile (S) can be obtained as described in EP B1 347 066 - diol) is prepared by ring closure in a retained configuration. The amount of R- cypran relative to s- cymidine in the product ethidium must be less than 3%. Furthermore, a method is described in WO 03000672 A process for the preparation of a mixture of R- and S-sirram containing more than 5 % s-mirrion isomers from a mixture of R- and S-diols containing more than 5 % r_diol.

從上面所述顯然可知者,需要具有上面所提鏡像異構 純度的消旋西普蘭和依西普蘭產物以用於醫藥組合物的製 備且依西普蘭產物可以經由RS_二醇與R_二醇及/或3_二 醇的閉環而製備成。其結果’需要有能製備具有相應鏡像 異構純度的消旋二醇和S _二醇產物之方法。 製備和醇化R-或S-二醇產物所用的方法都為可取用到 者。此等方法包括例如鏡像選擇性合成法如在Ep 〇347〇66 之中所述及者,傳統拆分(resGluti()n)和層析分離如在It will be apparent from the above that it is desirable to have the racemic cisplatin and ethiprom products of the above-described imagery isomer purity for the preparation of pharmaceutical compositions and the eciram product can be via RS_diol and R_two. It is prepared by ring closure of alcohol and/or 3-diol. As a result, a method of preparing a racemic diol having a corresponding mirror image purity and an S-diol product is required. The methods used to prepare and alcoholize the R- or S-diol product are all desirable. Such methods include, for example, mirror-selective synthesis as described in Ep 〇 347 〇 66, conventional resolution (resGluti() n) and chromatographic separation as in

W〇〇3006449之中所述及者。依照所使用的特殊方法與條 件而定,纟S-二醇產物符合上述諸要求之前可以必須改 善s-二醇產物的鏡像異構純度。 令人言牙異者,頃發現經由使用本發明方法,可以將昂 貴但《無用的雜含著[二醇之醇產物容易地轉化成 s•二醇,彼等皆符合上述 有關鏡像異構純度的要求。 再者,經由使用本發明方法 可以將昂責但顯然無甩s 丄331605 :雜含著s-二醇之醇產物容易地轉化成兩種有價值的 =物’消旋二醇和R•二醇,彼等皆符合上述有關鏡像異構 純度的要求。 更特別者’本發明提出一種將具有超過5〇%的諸鏡像 異構物之-的起始非消旋性S_M4_(二曱胺基)小(4,_ =基)小祕丁基]_3·⑽基曱基)_苯腈混合物分離成為一 =含s-二元醇《R·二元醇的部份與一包括rs_二元醇的部 份’其中R-二元醇:S-二元醇的比例為等於i :【或比起 始R-和S-二元醇混合物中者更接近i : i。 本發明係重要者且非常有用者,特別是因為其提供一 種方便’冑宜且有效率的方法以將不符合上述有關鏡像異 構純度的要求之R-和S_二元醇混合物轉換成兩種符合上述 有關鏡像異構純度的要求之有價值的產物,rs•二元醇和 S-二醇(或R-二醇)。 於另-方面中,本發明提出一種方便,便宜且有效率 « 的方法用以製造—種中間產物以用於西普蘭和依西普蘭的 製造之中。 使用^發明時,製造符合個別市場認可要求的西普蘭 和依西普蘭之方法在有關方法的簡單性和藥劑與資源的利 用上即變得更為合理且更為經濟。 【發明内容1 發明簡述 因此,本發明係有關一種製備消旋二元醇自由鹼及/或 酸加成鹽及/或R-或S-二元醇自由鹼及/或酸加成鹽的方法- 10 1331605 ’包括將含有超過50%的諸鏡像異構物之一的起始R和s_ 二兀醇自由鹼及/或酸加成鹽的非消旋性混合物分離成為一 田3 S 一元醇或尺_一元醇自由鹼及/或酸加成鹽的部份與 一包括RS-二元醇自由鹼及/或酸加成鹽的部份,其中R—二 元醇:s-二元醇的比例為等於i : i或比在起始R和8_二 元醇的混合物中者更接近1 : 1,其中 i)從該起始R-和S-二元醇自由鹼及/或酸加成鹽的 非消旋性混合物之溶液沉澱出RS_二元醇自由鹼及/或酸加 成鹽;或 攸《亥起始R-和S- 一元醇自由驗及/或酸加成鹽非消旋 性混合物在一溶劑中的溶液將R-或s·二元醇自由鹼及/或 酸加成鹽溶解在該溶劑内,留下包括RS_二元醇自由鹼及/ 或酸加成鹽的剩餘物; u)從最後溶液相分離出所形成的剩餘物/沉澱物; iia) 若該剩餘物/沉澱物為結晶型時,將其視需要再結 晶一或多次以形成消旋二元醇; iib) 若該剩餘物/沉澱物非為結晶型時,視需要重複步 驟1)和纟驟U)直到獲得結晶型剩餘物/沉澱物為止且將該 結晶型剩餘物/沉澱㈣需要再結晶一或多次以形成消旋二 元醇; Π1)視需要對該最後溶液相施以進一步純化且從最後溶 液相刀離出该3_二元醇或尺_二元醇自由鹼及/或酸加成鹽 iv)將所得二疋醇自由鹼視需要轉化成其酸加成鹽奭[ 9 1331605 將所得二元醇酸加成鹽視需要轉化成其他的酸加成鹽或將 . 所得二元醇酸加成鹽視需要轉化成相應的自由鹼^ · 據此,所得RS-二元醇自由鹼及/或酸加成鹽即可產生 -虽含S-或R_二元醇自由鹼及/或酸加成鹽任一者的最後溶 液相。剩餘的R-或S-二元醇自由鹼及/或酸加成鹽隨後即 可從最後溶液相按照下面所述分離出。 根據一特定具體實例,本發明係有關一種使用上述方 法製備消紅-—兀醇自由驗及/或酸加成鹽之方法。 根據另一特定具體實例,本發明係有關一種使用上述 鲁 方法製備S-二元醇(或R-二元醇)自由鹼及/或酸加成鹽之方 法0 根據又另一特定具體實例,本發明係有關一種所製備 的/肖旋二元醇自由鹼及/或酸加成鹽及/或s_二元醇(或R—二 =醇)自由鹼及/或酸加成鹽使用下面所述方法製備消旋西 普蘭及/或S-西普蘭(或R-西普蘭)自由鹼及/或酸加成鹽之 用途。As described in W〇〇3006449. Depending on the particular method and conditions employed, it may be necessary to improve the image-isolated purity of the s-diol product prior to meeting the above requirements for the 纟S-diol product. It is surprising that it has been found that by using the process of the invention, expensive but "useless miscellaneous [diol-alcohol products can be readily converted to s-diols, which all comply with the above-mentioned image isomer purity) Requirements. Furthermore, by using the method of the present invention, it is possible to easily convert the product of the alcohol containing the s-diol into two valuable substances, the racemic diol and the R diol, by using the method of the present invention. They all meet the above requirements for image isomer purity. More particularly, the present invention proposes an initial non-racemic S_M4_(diguanylamino) small (4, _ = yl) small butyl butyl group having more than 5% by weight of the mirror image isomers. · (10) fluorenyl) Benzonitrile mixture is separated into a = s-diol "R. diol part and a part comprising rs_ diol" where R-diol: S- The ratio of glycol is equal to i: [or closer to i: i than in the starting R- and S-diol mixture. The present invention is important and very useful, especially because it provides a convenient & efficient method for converting R- and S-diol mixtures that do not meet the above requirements for image isomer purity to two A valuable product that meets the above requirements for mirror image purity, rs•diol and S-diol (or R-diol). In another aspect, the present invention provides a convenient, inexpensive, and efficient method for making an intermediate product for use in the manufacture of celand and escitrin. When using the invention, the method of manufacturing ceplan and escitram that meets the requirements of individual market approvals becomes more reasonable and more economical in terms of the simplicity of the method and the utility of the pharmacy and resources. SUMMARY OF THE INVENTION Brief Description of the Invention Accordingly, the present invention relates to a process for preparing a racemic glycol free base and/or an acid addition salt and/or an R- or S-diol free base and/or an acid addition salt. Method - 10 1331605 'Including the separation of the non-racemic mixture of the starting R and s-diethanol free base and/or the acid addition salt containing more than 50% of the mirror image isomers into a field 3 S unitary a portion of an alcohol or a mono-alcohol free base and/or an acid addition salt and a portion comprising an RS-diol free base and/or an acid addition salt, wherein the R-diol: s-binary The ratio of alcohol is equal to i: i or closer to 1: 1 than in the mixture of starting R and 8_diol, where i) from the starting R- and S-diol free base and/or A solution of a non-racemic mixture of acid addition salts precipitates an RS_diol free base and/or an acid addition salt; or a "free start of R- and S-monohydric alcohol and/or an acid addition" A solution of the salt non-racemic mixture in a solvent dissolves the R- or s-diol free base and/or acid addition salt in the solvent, leaving the RS-diol free base and/or acid Residue of addition salt; u) from After the solution phase separates the formed residue/precipitate; iia) if the residue/precipitate is crystalline, it is recrystallized one or more times as needed to form a racemic glycol; iib) if the remainder When the substance/precipitate is not crystalline, step 1) and step U) are repeated as needed until a crystalline residue/precipitate is obtained and the crystalline form residue/precipitate (4) needs to be recrystallized one or more times to form Racemic Glycol; Π1) If necessary, the final solution phase is further purified and the 3 -glycol or saponin-diol free base and/or acid addition salt iv is removed from the final solution phase knife) The obtained diethanol free base is converted into its acid addition salt as needed [9 1331605. The obtained glycolic acid addition salt is converted into another acid addition salt as needed or the obtained glycolic acid addition salt is obtained. If necessary, the resulting RS-diol free base and/or acid addition salt can be produced - although containing S- or R-diol free base and / or acid addition The final solution phase of either salt. The remaining R- or S-diol free base and/or acid addition salt can then be separated from the final solution phase as described below. According to a particular embodiment, the invention relates to a process for the preparation of a red-and-sterol free test and/or an acid addition salt using the above process. According to another specific embodiment, the present invention relates to a process for the preparation of an S-diol (or R-diol) free base and/or an acid addition salt using the above-described method. According to yet another specific embodiment, The present invention relates to a prepared / spirulinol free base and / or acid addition salt and / or s - glycol (or R - bis = alcohol) free base and / or acid addition salt is used below The process employs the use of racemic cedar and/or S- cypress (or R- cypland) free base and/or acid addition salts.

發明之詳細說明 於本文件之中於任何時候用到之時,術語”弘二元醇” 和S-西普蘭二元醇,,意指s_4_[4_(二甲胺基)小(4,_氣苯基 八1-羥基丁基]-3-(羥基甲基)·苯腈。 於本文件之中於任何時候用到之時,術語” R_二元醇,, 和” R·西普蘭二元醇”意指R_4_[4•(二曱胺基)小(4,氟苯基 )-1-羥基丁基]-3-(羥基甲基)_笨腈。 於本文件之中於任何時候用到之時,術語” RS_二元酶 12 丄丄OU:) ”意指 R-和 ς 〇 ^ ΛΑ Λ c S•二元醇的混合物例如R-和S-二兀醇的0.5 : 或 0·9 . ll 或 0.95 : 1·〇5 或 0.98 : 1.02 或 0.99 : L01 扣°物且較佳者為R·和S-二元醇的1 : 1混合物。 :本文件之中於任何時候用到之時,術語”二元醇鏡像 異構物”和_ — , _ 4^ ―兀醇異構物,,意指s-或R-二兀酵任一者。 於本文件之中於任何時候用到之時,術語”消旋二元醇 思才曰R和S -二元醇的1 : 1混合物。術語”非消旋二元醇 σ物’思指R-和S-二元醇以1 : 1以外的比例之混合物。DETAILED DESCRIPTION OF THE INVENTION As used in this document at any time, the terms "Hong diol" and S- cypress diol, mean s_4_[4_(dimethylamino) small (4, qi Phenyl octa-l-hydroxybutyl]-3-(hydroxymethyl)·benzonitrile. As used in this document at any time, the term "R_diol, and" R. siplan II "Polyol" means R_4_[4•(diamidoamine) small (4,fluorophenyl)-1-hydroxybutyl]-3-(hydroxymethyl)-stanocarbonitrile. At any time in this document When used, the term "RS_binase 12 丄丄 OU:)" means a mixture of R- and ς 〇^ ΛΑ Λ c S• diol such as R- and S-diethanol 0.5 : or 0·9 . ll or 0.95 : 1·〇5 or 0.98 : 1.02 or 0.99 : L01 deduction and preferably a 1:1 mixture of R· and S-diol. : At any time in this document When used, the term "diol mirror image isomer" and _ - , _ 4^ - sterol isomer, meaning either s- or R-dialdehyde. Whenever used, the term "racemic diol" is a 1: 1 mixture of R and S - diols.The term "non-racemic diol σ" refers to a mixture of R- and S-diols in ratios other than 1:1.

於本文件之中於任何時候用到之時,術語”西普蘭鏡像 八構物和西普蘭異構物’,意指s-或R-西普蘭任一者。 於本文件之中於任何時候用到之時,術語”消旋西普蘭 忌指R-和s_西普蘭的1 : 1混合物。術語,,非消旋西普蘭” 意心R-和s_西普蘭以1 : 1以外的比例之混合物。 如在本說明部份中所使用者,術語,,沉澱,,意指從起始 一元醇非消旋混合物在一溶劑内的溶液形成沉殿物 曰曰體形式、非晶態固體或油狀物或彼等的混合物。於本As used at any time in this document, the term "Sipran mirrored eight-structure and sipram isomer" means either s- or R-Cypress. At any time in this document. When used, the term "racemic cymidine" refers to a 1:1 mixture of R- and s_ sipland. The term "non-racemic sipland" is intended to mean a mixture of R- and s_ cypress in a ratio other than 1:1. As used in this specification, the term, precipitation, means from the beginning A solution of a non-racemic mixture of monohydric alcohols in a solvent forms a sputum form, an amorphous solid or an oil or a mixture thereof.

說明部份中,沉澱物可為油狀物、非晶態固體或晶體或彼 專的混合物。 從起:t本說明部份:所使用者’術語”剩餘物”係指稱在 。_或S •二元醇非消旋混合物將R·或S -二-广〜 合劑内之後所殘留的剩餘物。該剩 二 晶態固體或油狀物或彼等的混合物之形式。4日日體、非 如在本文中所使用者’術語”剩餘物/沉澱 面所定義的沉澱物或剩餘物。 係扎稱上 13In the description, the precipitate may be an oil, an amorphous solid or a crystal or a mixture thereof. From: From the description of this part: the user's terminology "residue" is referred to as . _ or S • The non-racemic mixture of the diol will be the residue remaining after the R· or S-di-guang~ mixture. The remaining crystalline solid or oil or a mixture thereof. 4th day, non-precipitate or residue as defined by the user's terminology/precipitation surface as used herein.

OVD 本文中所使用者,術語,,母液,,(m〇t 從沉澱物蔣峪十八灿 〖quorj u日 牙夕除或刀離之後剩餘的溶劑。 抖二在ί文中所使用者,術語”從R-或S-二元醇的選擇 |·生/谷解所得到的有機 ,立 次水相日從起始R-或s-二元醇 非以化合物溶解出R-或s-二元醇所得相。 “二在本文中所使用者,術語,,最後溶液相,,係指稱於如 ^㈣S二元醇的選擇性溶解所得母液或有機及/ 或水相。 '如已經提及者,上述諸種製備西普蘭自由驗及/或酸加 成息及/或依西普蘭自由鹼及/或酸加成鹽所用的方法可能 導致不會被邊藥用途所接受# R•和s西普蘭自由驗及/或 酸加成鹽的混合物。根據本發明,已經發現到一種有驚人 效率的用以製備要製備消旋西普蘭自由驗及/或酸加成鹽與 R-或S·西普蘭自由驗及/或酸加成鹽所用的消旋二元醇及 R-或S-二το醇自由鹼及/或酸加成鹽之方法。 此種新穎方法包括將起始汉_和8_二元醇自由鹼及/或 酸加成鹽的非消旋性混合物分離成為一消旋二元醇自由鹼 及/或酸加成鹽的部份與一包括尺_或s_:元醇自由驗及/或 酸加成鹽的部❾。該消旋二元醇自由驗及/或酸加成鹽的部 份係經從一溶劑沉澱為油狀物、非晶態固體或晶體形式或 彼等的混合物,並從最後溶液相離析出尺_或s_二元醇自由 鹼及/或酸加成鹽。然後,可以從相應的消旋二元醇自由鹼 及/或酸加成鹽與R_或、二元醇自由鹼及/或酸加成鹽經由 閉環而形成消旋西普籣自由鹼及/或酸加成鹽與R_或s _西: 1331605 普蘭自由鹼及/或酸加成鹽。 根據本發明另一方面,係將起始汉 ° •和s·二元醇自由驗 及/或酸加成鹽的非消旋性混合物分離 ^ 醇或R-二元醇自由鹼及/或酸加成鹽 _ J。丨伤與一包括RS-二 元醇自由驗及/或酸加成鹽的部份,1OVD The user, term, mother liquor, (m〇t from the sediment 峪 峪 灿 〖 〖quorj u 牙 夕 夕 夕 夕 夕 夕 夕 夕 夕 夕 夕 夕 夕 夕 夕 夕 夕"From the choice of R- or S-diols | · raw / gluten-dissolved organic, the first aqueous phase from the starting R- or s-diol does not dissolve R- or s- two The phase obtained from the diol. "The user, term, and final solution phase, as used herein, refers to a mother liquor or an organic and/or aqueous phase obtained by selective dissolution of a s-diol such as s. The above-mentioned methods for preparing citrin free test and/or acid addition and/or ethidium free base and/or acid addition salt may result in not being accepted by the medicinal use. # R•和s西Mixan free test and / or acid addition salt mixture. According to the present invention, a surprisingly efficient preparation for the preparation of racemic cymidine free and / or acid addition salts with R- or S · West has been found Method for freely detecting and/or acid addition salt of racemic diol and R- or S-dioxa alcohol free base and/or acid addition salt Such novel methods include the separation of the non-racemic mixture of the starting han and 8 diol free bases and/or acid addition salts into a racemic diol free base and/or acid addition salt. And a part comprising a ruler or s_: a free alcohol and/or an acid addition salt. The part of the racemic diol free test and/or acid addition salt is precipitated from a solvent to an oil , amorphous solid or crystalline form or a mixture thereof, and the ruler or s_diol free base and/or acid addition salt is separated from the final solution. Then, the corresponding racemic The steroid free base and/or the acid addition salt and the R_ or diol free base and/or acid addition salt form a racemic cisplatin free base and/or an acid addition salt and R_ or via a ring closure s _ West: 1331605 Planan free base and / or acid addition salt. According to another aspect of the invention, the non-racemic nature of the initial HCl and s diol free test and / or acid addition salt The mixture is separated from alcohol or R-glycol free base and/or acid addition salt _ J. 丨 injury and a portion including RS-diol free test and/or acid addition salt, 1

''甲R-二元醇:S-二 元醇的比例為等於1: i或比在起始R ^ ύ - — X醇的混合 物中者更接近1: 1,包括將起始汉_和 _ ^ —疋醇自由驗及/ 或酸加成鹽的非消旋性混合物盥一,玄 _ /、,合劑混合且使得R-或S- 二元醇自由驗及/或酸加成鹽優先溶解 、 丨文疋/合解在該溶劑内,接著從 R-或S - 一元醇自由驗及/或酸力π成a 取盟的選擇性溶解所得到 的有機及/或水相分離出未溶解的RS -;辟ώ丄 肝J Kb·—兀酵自由鹼及/或酸 加成鹽及從該溶劑離析出R_戋s _ 4 兀醇自由鹼及/或酸加 成鹽。 ☆根據本發明此具體實例所使用㈣劑可為任何溶劑其 此促使R-或S-一兀醇自由驗及/或酸加成鹽優先溶解而以 剩餘物形式留T RS-二元醇自由鹼及/或酸加成鹽之混合物 ,其中R_二元醇:s-二元醇的比例為等於1 : 1或比在起 _ 始R-和S-二元醇的混合物中者更接近i : i。 於本發明方法中使用到的起始尺_和S —二元醇自由鹼及 /或酸加成鹽的非消旋混合物可為油狀物、非晶態固體或結 晶形式;或彼等的混合物。 步驟1)中形成的剩餘物/沉澱物可為油狀物、非晶態固 體或結晶形式或彼等的混合物。步驟i)中形成的剩餘物/沉 澱物較佳者為結晶形式。 15 1331605 根據本發明一具體實例,本發明方法中使用的起始R_ 和S-一 70醇自由鹼及/或酸加成鹽之非消旋混合物含有超 過50%的S-二元醇’或更佳者超過7〇%的s二元醇或最佳 者超過90%的S -二元醇。 根據本發明另一具體實例,本發明方法中使用的起始 R-和S-二元醇自由鹼及/或酸加成鹽之非消旋混合物含有 少於99.9%的S-二元醇,例如少於99.5。/。的s-二元醇,或 少於99°/。的S-二元醇,或少於98°/。的S-二元醇。 據此,該起始R-和S-二元醇自由鹼及/或酸加成鹽之 非消旋混合物可含有50%-98%的S-二元醇,或50%_99❶/〇的 S-二元醇,或 50%-99.5%的 S-二元醇,或 50%_99.9%的 S_ 二元醇,或70%-98。/。的S-二元醇,或70%_99%的S-二元 醇’或70%-99·5%的S-二元醇,或70%-99.9%的S-二元醇 ’或90%-98%的S-二元醇,或90%- 99%的S-二元醇,或 90°/。-99.5%的1二元醇,或90%-99.9%的8-二元醇。 根據本發明另一具體實例,本發明方法中使用的起始 R-和S-二元醇自由鹼及/或酸加成鹽之非消旋混合物含有 超過50%的R-二元醇’或更佳者超過7〇%的尺_二元醇或 最佳者超過90。/。的R-二元醇。 根據本發明又另一具體實例,本發明方法中使用的起 始R-和S-二元醇自由鹼及/或酸加成鹽之非消旋混合物含 有少於99.9%的R-二元醇,例如少於99.5%的R-二元醇, 或少於99%的R-二元醇’或少於98%的R-二元醇。 據此’該起始R-和S-二元醇自由鹼及/或酸加成鹽之[ 16 1331605 非消旋混合物可含有50%_98%的R_二元醇,或50%-99% · 的R-二元醇,或5〇%-99.5%的R-二元醇,或50%-99.9%的 . R-二元醇,或 70%_98% 的 R-二元醇,或 70%-99% 的 R-二 元醇,或70%-99.5%的R-二元醇,或70%-99.9%的R-二元 醇’或90%_98%的R-二元醇,或90%-99%的R-二元醇, 或 90〇/。-99.5%的 R_二元醇,或 90%-99.9%的 R-二元醇。 該方法可經重複進行直到獲得r_和S-二元醇的消旋混 合物為止及/或直到獲得合意的鏡像異構純度之尺_或§_二 元醇為止。 _ 根據本發明一具體實例,剩餘物/沉澱物的RS-二元醇 係呈自由鹼及/或酸加成鹽之形式;且最後溶液相的R_或 S-二元醇係獨立地呈自由鹼及/或酸加成鹽之形式。據此, 當剩餘物/沉澱物中所包括的RS_二元醇係呈自由鹼形式之 時’則最後溶液相中所包括的尺_或s_二元醇可呈自由鹼, 酉文加成鹽或自由驗和酸加成鹽的混合物之形式。再者,當 剩餘物/沉澱物中所包括的Rs_二元醇係呈酸加成鹽形式之 蛉,則最後溶液相中所包括的尺_或s_二元醇可呈自由鹼,鲁 酉文加成鹽或自由驗和酸加成鹽的混合物之形式。最後,當 剩餘物/沉澱物中所包括的RS_二元醇係自由鹼和酸加成鹽 的/¾ δ物之時,則隶後溶液相中所包括的I或二元醇可 呈自由鹼,酸加成鹽或自由鹼和酸加成鹽的混合物之形式 〇 本發明方法中使用的起始R-和S_二元醇非消旋混合物 可呈自由鹼,鹽或自由鹼和鹽的混合物之形式。 [$】 17 !3316〇5 再者,可以使用諳於此技者已知的方法將所得二元醇 _ 自由鹼可視需要轉化成其酸加成鹽或將所得二元醇酸加成. 鹽視需要轉化成其他的酸加成鹽或將所得二元醇酸加成鹽-視而要轉化成相應的自由驗。 RS-二元醇自由鹼的製備可經由取得反_和s—二元醇自 由鹼及/或酸加成鹽的非消旋混合物或將R和s-二元醇自 由鹼及/或酸加成鹽的非消旋混合物溶解在一適當溶劑之内 ’視需要予以加熱,且接著使溶液冷卻,或經由冷卻到低 於周溫之下而進行。之後從母液分離出沉澱物,較佳者係鲁 經由過濾或傾析(decanting)。 RS-二元醇自由鹼剩餘物可以經由從起始汉_和二元 ^ ^由鹼及/或酸加成鹽的非消旋混合物在一溶劑之内將 或S-二元醇自由鹼及/或酸加成鹽選擇性地溶解在該溶 劑之内而形成、然後從尺_或s_二元醇選擇性地溶解所得有 機及/或水相分離出剩餘物。 若剩餘物/沉澱物為結晶型,可以視需要將晶 —式炙 Λ* ττ、、、。曰曰 從該消==二元醇自由驗。然後,經由閉環· 並 疋—几酵自由驗形成消旋西普蘭自由驗。該消旋西 酸I。由鹼可以視需要轉化成其酸加成鹽’較佳者為氫演 剩餘物/沉澱物為油狀物 i)和步驄士 ,β …。从夏複 再結日_ U 料結晶產物為止°所得晶體可以視需要 、’〇日日一或多次以形成消旋二元醇自由鹼。消旋西並 由驗可以從該消旋二元醇自由驗經由閉環反應而形成閲二 18 1331605 以視需要將消旋西普蘭自由鹼轉化成其酸加成鹽,較佳者 為氫溴酸鹽。 根據本發明製備成的RS -二元醇自由鹼可以視需要轉 化成其酸加成鹽。 對於從最後溶液相分離出的油相可以視需要施以習用 的純化程序。 根據本發明製備成的RS -二元醇自由驗可能含有少量 剩餘S-二元醇(或R_二元醇)。因此可能需要對RS_二元醇 自由鹼重複i)和步驟ii)(特別是結晶化)一或多次以獲得消 方疋一元醇。可以將最後溶液合併在一起且可以按照下面所 述離析出其中所含二元醇鏡像異構物。 為了得到包括RS-二元醇自由鹼的剩餘物/沉澱物所用 的適當溶劑為非極性溶劑例如烧類,如庚院或己烧;芳族 經類例如甲苯’苯和二甲苯;極性溶劑例如乙腈,醇類例 如甲醇和異丙醇或酮類例如甲基異丁基酮;或彼等的混合 物。 於一較佳具體實例中,在步驟丨)中係得到RS二元醇 自由鹼’較佳者係呈結晶形式。 於需要時,結晶化可以經由用消旋結晶型結晶二元醇 自由驗。 RS-二元醇酸加成鹽的沉澱可以經由取得r—和s_二元 醇自由鹼或酸加成鹽的非消旋混合物或將反_和8_二元醇自 由驗或加成鹽的非消旋混合物〉谷解在—適當溶劑内,於 需要時施加熱’且添加酸,例如呈固體、液體,在溶液朽s 1331605 或氣體等形式者而進行。 . 將RS-二元醇酸加成鹽沉澱所用的酸為可沉澱尺_和s- -鏡像異構物的混合物且富含呈自由鹼或酸加成鹽形式的R-. 或S -二元醇鏡像異構物之母液之酸。 將R S - 一元醇酸加成鹽沉殿所用的酸可以: •取得起始R-和S-二元醇自由鹼及/或酸加成鹽的非 消旋混合物或將起始r_和8_二元醇自由鹼或酸加成鹽的非 消旋混合物溶解在一適當溶劑内之後添加;及/或 •在起始R-和S-二元醇自由鹼及/或酸加成鹽的非消 籲 旋混合物的溶解期間及/或之前存在於溶劑之中;及/或 •在溶解於溶劑内期間及/或之前存在於起始R-和S-二兀醇自由鹼及/或酸加成鹽的非消旋混合物之中。 RS-二元醇自由鹼剩餘物可以經由從起始r—和s_二元 醇自由鹼及/或酸加成鹽的非消旋混合物在一溶劑之内將 R-或S-二元醇自由鹼及/或酸加成鹽選擇性地溶解在該溶 劑之内,於需要時添加酸,例如呈固體、液體,在溶液中 或氣體等形式者而形成。 · 步驟丨)中所形成剩餘物所含RS-二元醇酸加成鹽的酸 部份為一酸’該酸可選擇性地溶解R-或S-二元醇自由鹼及 /或I加成鹽且留下富含RS_二元醇酸加成鹽的未溶解物質 〇 形成剩餘物所含RS-二元醇自由鹼所用的酸可以: •在起始R-和S_二元醇自由鹼及/或酸加成鹽的非消 旋α物與該溶劑混合之前存在於該溶劑之内;及/或[s ] 20 1331605 •與該溶劑和該起始R-和S-二元醇自由鹼及/或酸加 成鹽的非消旋混合物混合在一起;及/或 •在該起始R_和8_二元醇自由鹼及/或酸加成鹽的非 消旋混合物與該溶劑混合之後’才與該溶劑混合;及/或 •與溶劑混合期間及/或之前存在於該起始R-和S-二 元醇自由驗及/或酸加成鹽的非消旋混合物之中。''A R-glycol: S-glycol ratio is equal to 1: i or closer to 1:1 than in the starting R ^ ύ - X alcohol mixture, including the starting Han_ and _ ^ - sterol free test and / or non-racemic mixture of acid addition salts 盥, _ _,, mixture mixture and make R- or S- diol free test and / or acid addition salt priority Dissolving, hydrazine/recombination in the solvent, followed by separation of the organic and/or aqueous phase from the R- or S-monohydric alcohol free test and/or the selective dissolution of the acid force π into a Dissolved RS -; diarrhea liver J Kb - lysate free base and / or acid addition salt and from the solvent to isolate R 戋 s _ 4 sterol free base and / or acid addition salt. ☆ The agent used in this embodiment according to the present invention may be any solvent which promotes the free detection of R- or S-sterol and/or the preferential dissolution of the acid addition salt to leave the T RS-diol free as a residue. a mixture of bases and/or acid addition salts, wherein the ratio of R_diol:s-diol is equal to 1:1 or closer than in the mixture of R- and S-diols i : i. The non-racemic mixture of the starting ruthenium and S-diol free base and/or acid addition salt used in the process of the invention may be in the form of an oil, an amorphous solid or a crystalline form; or mixture. The residue/precipitate formed in step 1) may be in the form of an oil, an amorphous solid or a crystalline form or a mixture thereof. The remainder/precipitate formed in step i) is preferably in crystalline form. 15 1331605 According to one embodiment of the invention, the non-racemic mixture of the starting R_ and S-70 alcohol free bases and/or acid addition salts used in the process of the invention contains more than 50% of the S-diol' or More preferably, more than 7 % s diol or more preferably more than 90% S diol. According to another embodiment of the invention, the non-racemic mixture of the starting R- and S-diol free base and/or acid addition salt used in the process of the invention contains less than 99.9% S-diol, For example less than 99.5. /. S-diol, or less than 99 ° /. S-diol, or less than 98 ° /. S-diol. Accordingly, the non-racemic mixture of the starting R- and S-diol free base and/or acid addition salt may contain 50%-98% S-diol, or 50%_99❶/〇S. a glycol, or 50% to 99.5% S-diol, or 50% to 99.9% S-diol, or 70%-98. /. S-diol, or 70%_99% S-diol' or 70%-99.5% S-diol, or 70%-99.9% S-diol' or 90% - 98% S-diol, or 90% - 99% S-diol, or 90 ° /. - 99.5% of 1 glycol, or 90% - 99.9% of 8-diol. According to another embodiment of the invention, the non-racemic mixture of the starting R- and S-diol free base and/or acid addition salt used in the process of the invention contains more than 50% R-diol' or More preferably, more than 7 % of the metric diol or diol is more than 90. /. R-diol. According to still another embodiment of the present invention, the non-racemic mixture of the starting R- and S-diol free base and/or acid addition salt used in the process of the invention contains less than 99.9% R-diol For example, less than 99.5% of R-diols, or less than 99% of R-diols or less than 98% of R-diols. Accordingly, the starting R- and S-diol free base and/or acid addition salt [16 1331605 non-racemic mixture may contain 50%_98% R_diol, or 50%-99% · R-diol, or 5〇%-99.5% R-diol, or 50%-99.9%. R-diol, or 70%_98% R-diol, or 70 %-99% R-diol, or 70%-99.5% R-diol, or 70%-99.9% R-diol' or 90%_98% R-diol, or 90%-99% R-glycol, or 90〇/. -99.5% R-diol, or 90%-99.9% R-diol. This process can be repeated until a racemic mixture of r- and S-diol is obtained and/or until a desired image isomer purity of the ruler or §-diol is obtained. According to one embodiment of the invention, the residue/precipitate RS-diol is in the form of a free base and/or an acid addition salt; and the final solution phase of the R_ or S-diol is independently Free base and / or acid addition salt form. Accordingly, when the RS_diol contained in the residue/precipitate is in the form of a free base, then the ruler or s_diol included in the final solution phase may be a free base, 酉文加In the form of a salt or a mixture of free test and acid addition salts. Further, when the Rs_diol included in the residue/precipitate is in the form of an acid addition salt, the ruler or s_diol included in the final solution phase may be a free base, A mixture of a sulfonium salt or a free test and an acid addition salt. Finally, when the RS_diol contained in the residue/precipitate is a free base and a /3⁄4 δ of the acid addition salt, the I or glycol included in the solution phase can be free. a base, an acid addition salt or a mixture of a free base and an acid addition salt. The starting R- and S-diol non-racemic mixture used in the process of the invention may be a free base, a salt or a free base and a salt. The form of the mixture. [00] 17 !3316 〇 5 Further, the obtained diol _ free base can be converted into its acid addition salt or added to the obtained glycol acid using a method known to those skilled in the art. Conversion to other acid addition salts or addition of the resulting glycolic acid as needed - is converted to the corresponding free test. The preparation of the RS-glycol free base can be carried out by obtaining a non-racemic mixture of the anti- and s-diol free base and/or the acid addition salt or by adding the R and s-diol free base and/or acid. The salt-forming non-racemic mixture is dissolved in a suitable solvent 'heated as needed, and then the solution is allowed to cool, or via cooling to below ambient temperature. The precipitate is then separated from the mother liquor, preferably by filtration or decanting. The residue of the RS-glycol free base can be treated with a S-glycol free base in a solvent via a non-racemic mixture of starting and/or acid addition salts from the starting and/or binary / or acid addition salt is selectively dissolved in the solvent to form, and then the residue is separated from the organic and / or aqueous phase obtained by selective dissolution of the ruler or s_diol. If the residue/precipitate is crystalline, the crystal may be 炙 Λ * ττ, , , , as needed.自由 Free from the elimination == glycol. Then, through the closed loop and the 疋----------------------------- The racemic acid I. From the base, it can be converted into its acid addition salt as needed, preferably hydrogen residue/precipitate as oil i) and step gentleman, β .... The crystal obtained may be formed one or more times from day to day to form a racemic glycol free base from the day after the reconstitution of the U. Racemic and can be formed from the racemic glycol free test via a ring closure reaction to form a second 18 1331605 to convert the racemic celand free base to its acid addition salt, preferably hydrobromic acid, as needed salt. The RS-diol free base prepared according to the present invention can be converted to its acid addition salt as needed. For the oil phase separated from the final solution phase, a conventional purification procedure can be applied as needed. The RS-diol free test prepared according to the present invention may contain a small amount of residual S-diol (or R-diol). It may therefore be necessary to repeat i) and step ii) (especially crystallization) one or more times for the RS_diol free base to obtain the oxime monol. The final solutions can be combined together and the diol mirror image isomers contained therein can be isolated as described below. Suitable solvents for obtaining the residue/precipitate comprising the RS-diol free base are non-polar solvents such as calcinations such as Gengyuan or hexane; aromatics such as toluene 'benzene and xylene; polar solvents such as acetonitrile Alcohols such as methanol and isopropanol or ketones such as methyl isobutyl ketone; or mixtures thereof. In a preferred embodiment, the RS diol free base in the step 丨) is preferably in crystalline form. Crystallization can be carried out freely by using a racemic crystalline crystalline diol as needed. Precipitation of the RS-dibasic acid addition salt can be carried out by obtaining a non-racemic mixture of the r- and s-diol free base or acid addition salt or by freely or adding a salt of the anti- and 8-diol The non-racemic mixture 〉 gluten is carried out in a suitable solvent, applying heat when needed, and adding an acid, for example, as a solid, a liquid, in the form of a solution s 1331605 or a gas. The acid used for the precipitation of the RS-dibasic acid addition salt is a mixture of a precipitable ruler and an s--mirrogram isomer and is enriched in R-. or S-di in the form of a free base or an acid addition salt. The acid of the mother liquor of the alcohol mirror image isomer. The acid used in the addition of RS-monohydric acid to the salt can be: • obtain a non-racemic mixture of the starting R- and S-diol free base and/or acid addition salt or will start r_ and 8 Adding a non-racemic mixture of a glycol free base or an acid addition salt after dissolution in a suitable solvent; and/or • at the beginning of the R- and S-diol free base and/or acid addition salt The non-disintegration mixture is present in the solvent during and/or prior to dissolution; and/or • is present in the starting R- and S-dittanol free base and/or acid during and/or prior to dissolution in the solvent Addition of the salt to the non-racemic mixture. The RS-diol free base residue may be a R- or S-diol in a solvent via a non-racemic mixture of starting r- and s-diol free base and/or acid addition salt The free base and/or acid addition salt is selectively dissolved in the solvent, and an acid is added as needed, for example, in the form of a solid, a liquid, a solution or a gas. · The acid portion of the RS-dibasic acid addition salt contained in the residue formed in the step 为) is an acid which selectively dissolves the R- or S-diol free base and/or I plus Forming a salt and leaving an undissolved substance rich in RS_dibasic acid addition salt to form a residue. The acid used in the RS-diol free base can be: • at the starting R- and S-diol a non-racemic alpha salt of a free base and/or an acid addition salt is present in the solvent prior to mixing with the solvent; and/or [s] 20 1331605 • with the solvent and the starting R- and S- binary a non-racemic mixture of an alcohol free base and/or an acid addition salt; and/or a non-racemic mixture of the starting R_ and 8_diol free base and/or acid addition salt and Mixing the solvent with the solvent; and/or • a non-racemic mixture of the starting R- and S-diol free test and/or acid addition salt during and/or prior to mixing with the solvent Among them.

要從该起始R-和S-二元醇自由鹼及/或酸加成鹽的非 消旋混合物形成RS_二元醇酸加成鹽的剩餘物/沉澱物所用 的適當酸為無機酸例如鹽酸、氫溴酸、和硫酸,或有機酸 例如草酸、對-曱苯磺酸、甲烷磺酸、和醋酸。較佳的酸為 氫溴酸、鹽酸、和草酸。在使用此等酸之時,會形成rs_ 二元醇的氫溴酸鹽' 鹽酸鹽、和草酸鹽,較佳者呈結晶形 式°適當者’使用高達10當量的酸。據此: η - f υ.4 旲耳, 0.4-0.6 莫耳’或 〇 9-1 1 莖旦 j5\; 1 R 〇 〇 τγ 丨·1莫耳,或U·2.2莫耳的酸對南 R-和S-二元醇自由鹼及/或酸加成鹽的非消旋混合物科The appropriate acid to be used as the inorganic acid from the non-racemic mixture of the starting R- and S-diol free base and/or acid addition salt to form the residue/precipitate of the RS-dibasic acid addition salt For example, hydrochloric acid, hydrobromic acid, and sulfuric acid, or organic acids such as oxalic acid, p-toluenesulfonic acid, methanesulfonic acid, and acetic acid. Preferred acids are hydrobromic acid, hydrochloric acid, and oxalic acid. When such acids are used, the hydrobromide 'hydrochloride salt of the rs-diol and the oxalate salt are formed, preferably in the form of a crystal. Suitable for use as high as 10 equivalents. According to this: η - f υ.4 旲 ears, 0.4-0.6 Mo' or 〇9-1 1 stems j5\; 1 R 〇〇τγ 丨·1 moule, or U·2.2 mol acid to the south Non-racemic mixture of R- and S-diol free bases and/or acid addition salts

括的每一莫耳S-和R-二元醇;及/或 • 0.3-4.0莫耳,例如〇 4 〇 6莫耳,或〇 Μ」莫耳, 或1.8-2.2莫耳的酸對剩餘物/沉澱物中所包括的每 RS-二元醇。 吴斗Each mole of S- and R-diol; and / or • 0.3-4.0 moles, such as 〇4 〇6 moles, or 〇Μ"mol, or 1.8-2.2 moles of acid to the remainder Each RS-diol included in the substance/precipitate. Wu Dou

為了增加溶液的離子強度,可以在步驟i)中得到RS 二元醇酸加成鹽之前、期間或之後於溶液中添加鹽類例如 就卜諳於此技者都知道如何調整鹽的加 效應。 于引δ思的 21 Ϊ331605 要從起始R-和S-二元醇自由鹼及/或酸加成鹽的非… 旋混合物形成RS_二元醇酸加成鹽的剩餘物/沉澱物所用肩 適當溶劑為極性和非極性溶劑例如甲苯、乙酸乙奶、的 曰、乙麵 、THF、醇類例如異丙醇,乙腈,和酮類例如丙_和甲 異丁基嗣,及水。 土 若步驟i)中所形成的剩餘物/沉澱物為結晶者之時, 將該晶體從最後溶液相分離出,較佳者係經由過濾或傾^ 。可以勢需需要將晶體經由溶解在一溶劑之内,較佳者 以加熱,且接著使溶液冷卻,或經由冷卻到低於周溫之^ 而進行再結晶。消旋西普蘭可以從結晶型消旋二元醇酸加 成鹽經由閉環反應而形成。消旋西普蘭可以轉化成其藥學 上可接受的鹽,較佳者為HBr鹽。 ”予 若步驟i)中所形成的剩餘物/沉澱物為非結晶者,而是 非晶態或油狀物,或彼等的混合物之時,可重複步驟 步驟ii)直到獲得結晶型產物為止。 要按,日,?、上述再結晶一或多攻。消始 閱0j Μ攸結晶型消 。消旋西普蘭可以 鲁 °所得到的晶體可以視需In order to increase the ionic strength of the solution, it is possible to add a salt to the solution before, during or after the RS glycolic acid addition salt in step i). For example, it is known in the art how to adjust the additive effect of the salt. 21 Ϊ 331605, which is used to form a residue/precipitate of RS_dibasic acid addition salt from a non-... spin mixture of starting R- and S-diol free base and/or acid addition salt Suitable solvents for the shoulder are polar and non-polar solvents such as toluene, ethyl acetate, hydrazine, ethyl bromide, THF, alcohols such as isopropanol, acetonitrile, and ketones such as propyl and methyl isobutyl hydrazine, and water. Soil If the residue/precipitate formed in step i) is crystalline, the crystal is separated from the final solution phase, preferably by filtration or tilting. It may be desirable to crystallize the crystals by dissolving them in a solvent, preferably by heating, and then cooling the solution, or by cooling to below ambient temperature. Racemic cedar can be formed from a crystalline racemic glycolic acid addition salt via a ring closure reaction. Racemic cedar can be converted to a pharmaceutically acceptable salt thereof, preferably a HBr salt. "If the residue/precipitate formed in step i) is amorphous, but amorphous or oily, or a mixture thereof, step ii) may be repeated until a crystalline product is obtained. To press, day, ?, the above recrystallize one or more attacks. After reading 0j Μ攸 crystal type elimination. The crystal obtained by racemic siplan can be as needed

22 下面所述離析出其中所含二元醇鏡像異構物。 於而要時’可以經由用消旋結晶型二元醇酸加成鹽接 種來起始RS-二元醇酸加成鹽的結晶化。 醇酸加成鹽可視需要轉化 根據本發明製成的RS-二元 成其他酸加成鹽或相應的自由鹼 根據本發明一較佳具體實例,在步驟i)、iia)和iib)中 得到RS- 一元醇的自由鹼或Rs_二元醇的鹽酸鹽、氫溴酸 鹽、和草酸鹽,較佳者係呈結晶形式。22 The diol mirror image isomer contained therein is isolated as described below. When desired, crystallization of the RS-dibasic acid addition salt can be initiated by seeding with a racemic crystalline glycolic acid addition salt. The alkyd addition salt can be converted, as desired, to form RS-binary to other acid addition salts or corresponding free bases according to the invention, in accordance with a preferred embodiment of the invention, obtained in steps i), iia) and iib) The free base of RS-monohydric alcohol or the hydrochloride, hydrobromide, and oxalate salt of Rs_diol is preferably in crystalline form.

;昌3 R或S - 一元醇自由驗及/或酸加成鹽的最後 溶液相、其萃取液,或相可以在蒸發溶劑之前施以習用純 化%序(例如使用活性碳、層析術等處理),及/或可以對其 施以一或多次根據本發明的Rs_二元醇自由鹼或RS_二元 醇酸加成鹽之進-步沉殿,以改善二元醇鏡像異構物產物 的鏡像異構純度。 R或S 一元醇自由驗及/或酸加成鹽可以經由使用 用程序例如溶劑蒸發,或於最後溶液相為酸性之情況中; Chang 3 R or S - monool free test and / or the final solution phase of the acid addition salt, its extract, or phase can be applied to the conventional purification before the evaporation of the solvent (for example, using activated carbon, chromatography, etc.) Treatment), and/or may be subjected to one or more steps of the Rs_diol free base or RS_dicarboxylic acid addition salt according to the present invention to improve the diol image The mirror image isomer purity of the product product. The R or S monohydric alcohol free test and/or the acid addition salt may be evaporated by using a procedure such as a solvent, or in the case where the final solution phase is acidic.

經由鹼化接著分離諸相或經由萃取R或8_二元醇自由鹼及 /或酸加成鹽接著蒸發溶劑,而從最後溶液相離析出。 對於田S 11或S - 一元醇自由驗及/或酸加成鹽的最後 溶液相、其萃取液,或相可以在從該1或s_二元醇自由鹼 及/或酸加成鹽離析出之前施以習用純化程序(例如使用舌 性碳、層析術等處理適當地,可以由諸於此技者所知的 方法將R-或S-二元醇沉澱成為磷酸鹽或草酸鹽。 經發現留在最後溶液相 中的R-或S -二元醇自由驗及卜 23 l33l6〇5 或酸加成鹽所具鏡像異構純度(在所要 v你所要的異構物與兩種異構 物的和之間的比例),依照所使欲的特殊條件,可能高達· 97-98 %或甚至於更高(亦即更好)。 因此之故,根據本發明製成的s_二元醇(或R-二元醇) 自由鹼及/或酸加成鹽可能含有少量的R二元醇(或s二元 醇)自由鹼及/或酸加成鹽。於一具體實例中,此等少量可 能少於3%,或更佳者少於2%,或最佳者少於1%(在少量 中所含異構物與兩種異構物的和之間的比例)。 R-或S- 一元醇自由驗及/或酸加成鹽可以按照上文所 鲁 述予以純化及從該溶劑或最後溶液相離析出。 於一具體實例中’係得到R_二元醇自由鹼或酸加成鹽 0 於另一具體實例中,係得到S-二元醇自由鹼或酸加成 鹽。 當得到的是R-或S-二元醇自由鹼之時,將其視需要轉 化成其酸加成鹽。當得到的是R-或S-二元醇酸加成鹽之時 ,將其視需要轉化成其他酸加成鹽或對應的自由鹼。 籲 可以將鏡像異構純的R-或S-二元醇自由鹼及/或酸加 成鹽與R-和S-二元醇自由鹼及/或酸加成鹽的非消旋混合 物混合而得到消旋二元醇自由鹼及/或酸加成鹽。然後可以 經由如上所述對消旋二元醇自由鹼及/或其酸加成鹽施以一 或多次沉澱,接著再結晶而得到消旋二元醇自由鹼及/或酸 加成鹽。 R-或S -西普藺自由驗及/或酸加成鹽可以從對應的Re· si 24 1331605 或s-二元醇自由驗及/或酸加成鹽經由閉環反應但保持構 型之下而形成。s-西普蘭(或R-西普蘭)自由鹼及/或酸加成 鹽可視需要轉化成其一酸加成鹽,較佳者草酸鹽且視需要 予以再結晶。 R-或S-二元醇自由鹼及/或酸加成鹽的閉環反應可以 通過一不安定性中間產物,例如在甲苯磺醯氣存在中,於 一驗性環境中實施,如於EP-B1-347 066中所述者。然後 ,在保持立體化學之下進行閉環反應。之後可以得到具有 實質等於起始二元醇的鏡像異構純度之汉_或s_西普蘭自由 驗及/或酸加成鹽。 所%•消紅一元醇自由驗及/或酸加成鹽得環閉合可以在 酸性環境中,如在US 4,650,884中所述者,或如上所述透 過一不安定性酯實施。由是,得到消旋西普蘭。 可以將如此所得鏡像異構純的R_或s-西普蘭自由鹼及 /或S欠加成鹽與R-和S -西普蘭自由驗及/或酸加成鹽的非消 旋混合物混合而得到消旋西普蘭自由鹼及/或酸加成鹽。然 後可以經由如上所述對西普蘭自由鹼或其酸加成鹽施以— 或多次 >儿殿’接著再結晶而得到消旋西普蘭自由驗及/或酸 加成鹽。 本發明一特別具體實例係有關一種製備消旋二元醇自 由鹼及/或其酸加成鹽及/或R_或3_二元醇自由鹼或其酸加 成鹽的方法,包括將含有超過5〇%的諸鏡像異構物之—的 起始R-和S-二元醇自由鹼及/或酸加成鹽的非消旋性混合 物分離成為一富含S-二元醇或尺_二元醇的部份與—包掎 25 丄川005The phases are separated from the final solution by alkalization followed by separation of the phases or by extraction of R or 8-diol free base and/or acid addition salt followed by evaporation of the solvent. For the final solution phase of the S 11 or S - monohydric alcohol free radical test and / or acid addition salt, the extract thereof, or the phase may be separated from the 1 or s diol free base and / or acid addition salt Prior to precipitation, conventional purification procedures (e.g., treatment using lingual carbon, chromatography, etc., may be suitably employed to precipitate the R- or S-diol to phosphate or oxalate by methods known to those skilled in the art. The R- or S-diol that has been found to remain in the final solution phase is free to detect the image isomer purity of the 23 l33l6〇5 or acid addition salt (in the desired v, the desired isomer and two The ratio between the sum of the isomers, depending on the particular conditions desired, may be as high as -97-98% or even higher (i.e., better). Therefore, s_ made according to the present invention The diol (or R-diol) free base and/or acid addition salt may contain a small amount of R diol (or s diol) free base and / or acid addition salt. In a specific example These may be less than 3%, or more preferably less than 2%, or most preferably less than 1% (the ratio between the isomer contained in a small amount and the sum of the two isomers). The R- or S-monohydric alcohol free test and/or acid addition salt can be purified as described above and isolated from the solvent or the final solution. In one embodiment, the R-glycol free is obtained. Base or acid addition salt 0 In another embodiment, an S-diol free base or an acid addition salt is obtained. When an R- or S-diol free base is obtained, it is optionally taken. Conversion to its acid addition salt. When an R- or S-dibasic acid addition salt is obtained, it is converted to other acid addition salts or corresponding free bases as needed. Pure R- or S-diol free base and/or acid addition salt is mixed with a non-racemic mixture of R- and S-diol free base and/or acid addition salt to give a racemic glycol Free base and/or acid addition salt. The racemic diol can then be obtained by subjecting the racemic diol free base and/or its acid addition salt to one or more precipitations as described above, followed by recrystallization. Free base and / or acid addition salt. R- or S - citrate free test and / or acid addition salt can be freely tested and / or acid addition from the corresponding Re · si 24 1331605 or s-diol Formed via a ring closure reaction but maintained under configuration. The s- cymidine (or R- cypland) free base and/or acid addition salt can be converted to its acid addition salt as desired, preferably oxalate and Recrystallization as needed. The ring closure reaction of the R- or S-diol free base and/or acid addition salt can be carried out in an inert environment by a restorative intermediate, for example in the presence of toluenesulfonium. , as described in EP-B1-347 066. Then, the ring closure reaction is carried out while maintaining the stereochemistry. After that, it is possible to obtain an image or a s_ siplan which is substantially equal to the image isomer purity of the starting diol. Freely tested and/or acid-added salt. %•Red-doped monol free test and/or acid addition salt can be closed in an acidic environment, as described in US 4,650,884, or as described above. Unstable esters are implemented. Therefore, the racemic siplan is obtained. The thus obtained image-isomerically pure R_ or s- celand free base and/or S underdosed salt may be mixed with a non-racemic mixture of R- and S-Cymidine free and/or acid addition salts. A racemic celand free base and/or an acid addition salt is obtained. The racemic sirranin free test and/or acid addition salt can then be obtained by subjecting the cedar free base or its acid addition salt to - or multiple times & then recrystallization to the same as described above. A particular embodiment of the invention relates to a process for the preparation of a racemic glycol free base and/or an acid addition salt thereof and/or an R_ or 3_diol free base or an acid addition salt thereof, which comprises More than 5% by% of the smectic isomers - the starting R- and the S-glycol free base and / or the acid addition salt of the non-racemic mixture is separated into a S-diol or ruler _ diol part and - package 25 丄川005

•—元醇的部份,1φ ρ - 古.c - - A ,、T R-—兀醇· S-一兀醇的比例為等 . 於1 · 1或比在起始R-和s_二元醇的混合物中者更接近^ :1,其中 i)從一溶劑中沉澱出RS_二元醇為自由鹼或其酸加成 鹽形式; u)從母液中分離出所形成的沉澱物 ua) 若該沉澱物為結晶型時,將其視需要再結晶一或 夕次以形成消旋二元醇; ub) 若s亥沉澱物非為結晶型時,視需要重複步驟〇和鲁 ⑴直到獲得結晶型沉澱物為止且將該結晶型沉澱物視需要 再結晶一或多次以形成消旋二元醇; in)視需要對該母液施以進一步純化且從該母液離析出 該S-二元醇或R_二元; iv)將所得二元醇自由鹼視需要轉化成其酸加成鹽或將 所得二元醇酸加成鹽視需要轉化成其他的酸加成鹽或將所 得二元醇酸加成鹽視需要轉化成相應的自由鹼。 本發明一特別具體實例係有關一種製備消旋二元醇自 · 由驗或其酸加成鹽及/或R—或S_二元醇自由鹼或其酸加成 鹽的方法’包括將含有超過50%的諸鏡像異構物之一的起 始R-和S-二元醇的非消旋性混合物分離成為一富含5_二 元醇或R-二元醇的部份與一包括RS_二元醇的部份,其中 R-二元醇:S-二元醇的比例為等於1 : 1或比在起始R—和 s_二元醇的混合物中者更接近1: 1,其中 i)從一溶劑中沉澱出RS-二元醇為自由鹼或其酸加成] 26 !3316〇5 鹽形式; (。R和S _元醇的非消旋性混合物將R-或S-二 · 醇冷解在一溶劑内成為在該溶劑内的自由鹼或其酸加成鹽 之形式; Η)從母液中分離出所形成的沉澱物 lla)若該沉澱物為結晶型時,將其視需要再結晶一或 夕-欠以形成消旋二元醇; nb)若該沉澱物非為結晶型時,視需要重複步驟丨)和 u)直到獲得結晶型沉澱物為止且將該結晶型沉澱物視需要鲁 再結晶一或多次以形成消旋二元醇; 111)視需要對該母液施以進一步純化且從該母液離析出 §亥S-二元醇或二元; iv)將所得二元醇自由鹼視需要轉化成其酸加成鹽或將 所得二元醇酸加成鹽視需要轉化成其他的酸加成鹽或將所 得二元醇酸加成鹽視需要轉化成相應的自由鹼。 【實施方式】 本發明要用下面的諸實施例予以闡明,不過其不可以 0 視為具有限制性。 實施例 於下面的諸實施例中’光學純度係以手徵型SCFC (超 臨界流體層析術)HPLC予以測量。 實施例1 經由將消旋二元酵沉澱成鹽酸鹽以純化s_二元醇 通用方法: r _ 27 :R和s - 一元醇的混合物(如下面站志士 )(1〇克)溶解在甲苯(60毫并)中 所定義者 〗M、 ”本(60毫升)甲。加入鹽酸水溶液(32毫升 系坠It况中加入固體氣化鈉(足夠• The fraction of the alcohol, 1φ ρ - 古·c - - A , , T R--sterol · S-monosterol ratio, etc. at 1 · 1 or than at the beginning R- and s_ The mixture of glycols is closer to ^:1, wherein i) the RS_diol is precipitated from a solvent as a free base or an acid addition salt thereof; u) the precipitate formed is separated from the mother liquor ua If the precipitate is crystalline, recrystallize it as needed or once a day to form a racemic glycol; ub) If the precipitate is not crystalline, repeat the steps 〇 and Lu (1) as needed until Obtaining a crystalline precipitate and recrystallizing the crystalline precipitate one or more times as needed to form a racemic glycol; in) optionally purifying the mother liquor and isolating the S-di from the mother liquor a diol or R_ binary; iv) converting the resulting diol free base to its acid addition salt as needed or converting the resulting glycolic acid addition salt to other acid addition salts as needed or The alkyd addition salt is converted to the corresponding free base as needed. A particular embodiment of the invention relates to a process for the preparation of racemic glycols or their acid addition salts and/or R- or S-diol free bases or acid addition salts thereof, which will contain More than 50% of the non-racemic mixture of the starting R- and S-diols of one of the mirror image isomers is separated into a portion rich in 5-diol or R-diol and includes Part of the RS_diol, wherein the ratio of R-diol: S-diol is equal to 1:1 or closer to 1:1 than in the mixture of starting R- and s-diol , i) precipitating RS-diol from a solvent to a free base or its acid addition] 26 !3316 〇 5 salt form; (. R and S _ ol of a non-racemic mixture will be R- or The S-di-alcohol is cold-solved in the form of a free base or an acid addition salt thereof in the solvent; Η) separating the precipitate formed from the mother liquid lla) if the precipitate is crystalline Recrystallizing it as needed or forming a racemic glycol; nb) if the precipitate is not crystalline, repeat steps 丨) and u) as needed until a crystalline precipitate is obtained and Crystalline The precipitate is recrystallized one or more times as needed to form a racemic diol; 111) the mother liquor is further purified as needed and the sigma-S-diol or binary is isolated from the mother liquor; iv) The obtained diol free base is converted into its acid addition salt as needed or the obtained glycolic acid addition salt is converted into other acid addition salt as needed or the obtained glycolic acid addition salt is converted into a corresponding one as needed. Free base. [Embodiment] The present invention will be clarified by the following examples, but it is not considered to be limiting. EXAMPLES In the following examples, the optical purity was measured by chiral SCFC (Supercritical Fluid Chromatography) HPLC. Example 1 Purification of s-diol by precipitation of racemic binary yeast to a common method: r _ 27 : a mixture of R and s - monohydric alcohol (such as the following) (1 gram) dissolved in Toluene (60 mA) defined in the formula M, "this (60 ml) A. Add hydrochloric acid aqueous solution (32 ml suspension in the case of adding solid sodium sulphate (sufficient

NaC1在水中的濃度約為1 M)。將兮.曰人舲w 、网啫巧M)將5亥混合物搜拌整夜,且 過濾。將剩餘物乾燥而得雜含某此 _ 二元醇鹽酸踏晶體伸… 一酵鹽酸鹽的消旋 夂1日日體。使用氨水溶液將母液鹼化到 且分離出f苯層。用甲贫 肖甲本將水層再卒取—次,並將合併甲 Γίί s~二元醇。參看表中所列詳情。物質的回收率幾乎 ‘·'全!者,具有預期的在個別樣品之間的重量分配The concentration of NaC1 in water is approximately 1 M). The 亥 曰 曰 、 、 、 、 、 、 、 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 The residue is dried to obtain a miscellaneous _ diol hydrochloric acid stepping on the crystal... The crystallization of a yeast hydrochloride 夂 1 day. The mother liquor was alkalized using an aqueous ammonia solution and the f-benzene layer was separated. Use the hypothyroid shovel to smash the water layer again, and combine the 甲 Γίί s~ glycol. See the details listed in the table. The recovery rate of the substance is almost ‘·'! With the expected weight distribution between individual samples

---—ftp | |__0 U 表於扣合物中加入固體NaCl,足量使得所得水相有 約 1 M NaCM。 、液以硫酸鎂脫水及減壓蒸發而得内雜少量R_二元醇 於下面的諸貫施例中,光學純度係以手徵型HPLC予 以測量。 資施例2 經由將消旋二元》白山从 #u C - X* 耳由驗沉激以纯化S-— 7C酵 Γ t. 28----ftp | |__0 U Add solid NaCl to the carcass, enough to make the resulting aqueous phase about 1 M NaCM. The liquid was dehydrated with magnesium sulfate and evaporated under reduced pressure to give a small amount of R-glycol. In the following examples, the optical purity was measured by chiral HPLC. Example 2 Purification of S--7C Fermentation 将 t. 28 by crystallization of the racemic binary white mountain from #u C - X* ear

Claims (1)

13^05 —__ ·. 色告本丨(更)正本 拾、申清專利範圍: 1 · 種從起始R-和S-二元醇自由驗或其酸加成鹽的 -非消旋性混合物製備消旋西普蘭二元醇(,,消旋二元醇”)-自由驗或其酸加成鹽及/或對應R-或S-二元醇自由鹼或其 酸加成鹽的方法’包括下列步驟: 1)從該起始非消旋性混合物之溶液沉澱出呈自由鹼或 其酸加成鹽之R_和S-西普蘭二元醇的混合物(,,RS_二元醇 ’留下包括R-和S_二元醇自由鹼或其酸加成鹽的最後 溶液相,其中該沉澱出的Rs二元醇包含R_二元醇:3_二_ 兀醇的比例為等於1或比起始非消旋性混合物更接近1 :1 ;或將該起始非消旋性混合物的溶液與一溶劑混合以 優先將R-或S-二疋醇自由驗或其酸加成鹽溶解至最後溶液 相内留下包括rS_二儿醇自由驗或其酸加成鹽㈣餘物 Π)從最後溶液相分離出該剩餘物/沉澱物; 、—若該剩餘物/沉澱物為結晶型時,將該剩餘物/沉澱 物視需要再結晶-或多次以形成消旋二元醇;或 一,」叫若該剩餘物/沉澱物非為結晶型時,視需要重複步 驟i)和步驟ii)直到獲得結晶型剩餘物,沉澱物為止且將該 結晶型剩餘物/沉澱物視需要具处s . 丹m日日—或多次以形成消旋二 元酵; W)視需要對該最後溶液相施以進—步純化 V)從該最後溶液相分離出S _ _ 兀*每或R-二元醇自由鹼 或酸加成鹽; 36 1331605 via)將該S-二元醇或R-二元醇自由鹼視需要轉化成其 酸加成鹽; R-二元醇自由鹼的酸加成鹽視需 :或 R-二元醇自由驗的酸加成鹽視需 vib)將該S -二元酵或 要轉化成其他的酸加成鹽 vie)將該S -二元酵或 要轉化成相應的自由驗。13^05 —__ ·. The color of the book (more) is the original, the scope of the patent: 1 · the free R- and S-diol from the initial or its acid addition salt - non-racemic Mixture preparation of racemic cedar diol (,, racemic diol) - free test or its acid addition salt and / or corresponding R - or S - glycol free base or its acid addition salt 'Including the following steps: 1) Precipitating a mixture of R_ and S- cypland diols as a free base or an acid addition salt thereof from the solution of the starting non-racemic mixture (, RS_diol) 'Leaves a final solution phase comprising R- and S_diol free base or an acid addition salt thereof, wherein the precipitated Rs glycol comprises R_diol: the ratio of 3-di-sterol is Equivalent to 1 or closer to 1:1 than the starting non-racemic mixture; or mixing the solution of the starting non-racemic mixture with a solvent to preferentially test R- or S-dittanol or its acid Dissolving the salt into the final solution phase, leaving the rS_diol free test or its acid addition salt (4) residue Π) separating the residue/precipitate from the final solution phase; - if the residue/precipitate Object In the form of a crystal, the residue/precipitate may be recrystallized as needed - or multiple times to form a racemic glycol; or one, if the residue/precipitate is not crystalline, repeat step i as needed And step ii) until a crystalline residue, a precipitate is obtained and the crystalline residue/precipitate is optionally provided as s. 丹 m day- or multiple times to form a racemic binary yeast; W) The final solution phase needs to be subjected to further purification V) from the final solution phase to separate S _ _ 兀 * per or R-glycol free base or acid addition salt; 36 1331605 via) the S-two The alcohol or the R-glycol free base is converted to its acid addition salt as needed; the acid addition salt of the R-diol free base is as needed: or the acid addition salt of the R-diol free test is required Vib) The S-dialdehyde or to be converted into other acid addition salts vie) to convert the S-dialdehyde into a corresponding free test. 2. 一種從起始R-和S-二元醇自由鹼或其酸加成鹽的 非消旋性混合物製備S-西普蘭二元醇或西普蘭二元醇自由 驗或其酸加成鹽的方法,包括下列步驟: i)從該起始非消旋性混合物之溶液沉澱出呈自由鹼 或其酸加成鹽之R-和S_西普蘭二元醇的混合物(”Rs_二元 醇”),留下一最後溶液相’其中該沉澱出的RS_二元醇包 含R-二元醇:S-二元醇的比例為等於丨:1或比起始非消 旋I·生尾口物更接近1 . i ;或將該起始非消旋性混合物的溶 液與-溶劑混合以優先將R-或s_二元醇自由鹼或其酸加成2. Preparation of S-Cymidine glycol or cedar glycol free test or its acid addition salt from a non-racemic mixture of starting R- and S-diol free base or its acid addition salt The method comprises the steps of: i) precipitating a mixture of R- and S- cypland diols as a free base or an acid addition salt thereof from the solution of the starting non-racemic mixture ("Rs_ binary Alcohol"), leaving a final solution phase where the precipitated RS_diol contains R-glycol: the ratio of S-diol is equal to 丨:1 or is less than the initial non-racea I The tailings are closer to 1. i; or the solution of the starting non-racemic mixture is mixed with a solvent to preferentially add the R- or s-diol free base or its acid 鹽溶解至最後溶液相内,留下包肖RS-二元醇自由鹼或其 酸加成鹽的剩餘物; 出該剩餘物/沉澱物; 液相施以進·一步純化 出S-二元醇或R_二元醇 i i)從表後溶液相分離 iii) 視需要對該最後溶 由驗 iv) 從最後溶液相分離 及/或其酸加成鹽。 3 · 根據申請專利結阁外^ E _ 圍弟2項之方法,其中所製備的 醇為S 一元醇自由鹼或其酸加成鹽。 4·根據申°月專利範圍第2項之方法,其中所製備的 37 1331605 二元醇為R-二元醇自由鹼或其酸加成鹽。 5, 一種製備消旋西普蘭二元醇(,,消旋二元醇,,)自 由鹼或其酸加成鹽之方法,包括下列步驟: 〇從起始非消旋性混合物之溶液沉澱出呈自由鹼或 其酸加成鹽之R-和S_西普蘭二元醇的混合物(,,rs_二元醇 ),留下一取後溶液相,其中該沉澱出的Rs_二元醇包含 R- *~ · S - -H- 66 tf- /ε,ϊ ^ λ-λ- 例為寺於1 : 1或比起始非消旋性 混合物更接近1 : 1 ;式脾$ L ,,. 4將5亥起始非消旋性混合物的溶液與 一溶劑混合以優先將戋s _ __ 飞—凡醇自由驗或其酸加成鹽溶 解至最後溶液相内,留下包括 _ _ 枯RS - —元醇自由驗或其酸加 成鹽的剩餘物; π)從最後溶液相分離出該剩餘物/沉澱物; B)若該剩餘物/沉澱物為結晶型時,將其視需要再 結晶一或多次以形成消旋二元醇; )若該剩餘物/沉澱物非為結晶型時,視需要重複 步驟〇和U)直到獲得結晶型剩餘物/沉澱物為止且將該結 晶型剩餘物/沉澱物視需要再結晶—或多次以形成消旋二元 醇。 6. 根據申請專利範圍第i項之 ^ ^ ^ ^ 貝(方法,其中該起始非 消旋混合物含有超過50%的s_二元醇。 7. 根據申請專利範圍第1項之方法’其中該起始非 消旋混合物含有超過50%的R_二元醇。 8 ·根據申請專利範圍第1珀 鞄圍弟1項之方法,其中在該剩餘物/ 沉澱物之RS-二元醇中的R•二元 呼· s -—元醇之比例是在 38 1331605 0.5 : 1.5至1 : 1的範圍内。 9.根據申請專到範園第1項 把物的R ς - n〜么 、法’其中該剩餘物/沉 叙物的RS-一 τϋ醇和敢後溶液相的 地呈自由鹼或其酸加成鹽之形式。” _二几醇係各獨立 Α根據申請專利範圍第1項之方法,其中W 自由鹼或其酸加成鹽係從該起 凡口 澱出。 非“佳混合物之溶液沉 根據申請專利範㈣丨項 澱出RS-二元醇。 '、中你使用酸沉 Α根據申請專利範圍第u項之方法 消旋性混合物係取得或溶解在適當溶劑中且該酸^起始非 解在· ^ 2起始非消旋混合物或將起始非消相合物溶 解在一適當溶劑中之後添加; 初冷 劑中始非消旋混合物的溶解期間及/或之前存在於溶 合物;在溶解於溶劑中期間及/或之前存在於起始非消旋混 13.根據申請專利範圍第1項之方法, 起始非消旋性溫人私1 Μ — /、中係將5亥 二_ # 匕σ物的鉍液與一溶劑混合以優先將1或s_ 一醇自由驗岑1高上 一 括RS-二元醇自Γ 鹽溶解至最後溶液相内,留下包 目由驗或其酸加成鹽的剩餘物。 14·根據申請專利範圍第i項之方法 ^酸加成鹽係飛# A a T RS— ^ ' V成為具有包含酸的酸部份之殘餘物。 15·根據申請專利範圍第13項之方法,其中該酸恿。 39 1331605 •在起始非消旋混合物與該溶劑混合之前存在於該溶 劑内; X' •與該溶劑和該起始非消旋混合物混合在一起;及/或 •在該起始非消旋混合物與該溶劑混合之後與該溶劑 混合;及/或 Θ •在與溶劑混合期間及/或之前存在於該起始非消旋混 合物中。 16·根據申請專利範圍第14項之方法,其中該起始非 消旋混合物係與選自下列的溶劑混合:曱苯、乙酸乙酯、 乙醚、THF、水、醇類、乙腈、酮類及彼等的混合物。 17·根據申請專利範圍第!項之方法,其中該剩餘物/ 沉澱物的形成係使用選自下列的酸:HC1、HBr,H2S04、 對-甲苯磺酸、甲烷磺酸、醋酸及草酸。 1 8 根據申請專利範圍第1 7項之方法,其中該酸係選 自HC1、HBr及草酸。 一 19·根據申請專利範圍第1項之方法,其中該剩餘物/ 沉澱物的形成使用G2_1q莫耳的酸對起始非;肖旋混合物中 所包括的每一莫耳S-和R-二元醇。 …20.根據申請專利範圍第i項之方法,其中該剩餘物/ ^的形成使用〇.3-4.0莫耳的酸對剩餘物/沉澱物中 包括的每-莫耳RS_二元醇。 •μ诹宁請專利The salt is dissolved into the final solution phase, leaving the remainder of the RS-diol free base or its acid addition salt; the residue/precipitate; the liquid phase is applied and the S-binary is purified in one step. Alcohol or R_diol ii) phase separation from the post-sequence solution iii) If necessary, the final solution is iv) separated from the final solution phase and/or its acid addition salt. 3 · According to the method of applying for a patent, the alcohol prepared is an S monohydric alcohol free base or an acid addition salt thereof. 4. The method of claim 2, wherein the 37 1331605 diol is an R-glycol free base or an acid addition salt thereof. 5. A process for the preparation of a racemic cedar diol (, racemic diol, ) free base or an acid addition salt thereof, comprising the steps of: hydrating from a solution of the starting non-racemic mixture a mixture of R- and S_ cyram diols as a free base or an acid addition salt thereof (, rs_diol), leaving a post-removal solution phase in which the precipitated Rs_diol Contains R-*~ · S - -H- 66 tf- /ε, ϊ ^ λ-λ- for the temple at 1:1 or closer to 1:1 than the starting non-racemic mixture; spleen $ L , 4, mixing the solution of the starting non-racemic mixture of 5 hai with a solvent to preferentially dissolve the 戋s _ __ fly-form alcohol free test or its acid addition salt into the final solution phase, leaving _ _ a residue of free RS-formol or its acid addition salt; π) separating the residue/precipitate from the final solution phase; B) if the residue/precipitate is crystalline, Recrystallization needs to be repeated one or more times to form a racemic glycol; if the residue/precipitate is not crystalline, repeat steps 〇 and U) as needed until a crystalline residue/precipitate is obtained The crystalline residue/precipitate is recrystallized as needed - or multiple times to form a racemic glycol. 6. According to the patent application scope i of ^ ^ ^ ^ shell (method, wherein the starting non-racemic mixture contains more than 50% of s_diol. 7. according to the method of claim 1 of the ' The starting non-racemic mixture contains more than 50% of the R-diol. 8 · According to the method of claim 1 of the patent application, in the RS-diol of the residue/precipitate The ratio of R• binary s--alcohol is in the range of 38 1331605 0.5 : 1.5 to 1:1. 9. According to the application, the R ς - n~ The method 'where the residue/sinking substance of RS-monohydrazide and the solution phase of the solution is in the form of a free base or an acid addition salt thereof." _Dihydric alcohol is independent of each other according to the scope of claim 1 A method in which a W free base or an acid addition salt thereof is deposited from the mouth. A solution of a non-"good mixture is precipitated according to the patent application (IV). The RS-diol is precipitated. The racemic mixture obtained or dissolved in a suitable solvent according to the method of claim U of the patent application and the initiation of the acid The non-solution is added after the initial non-racemic mixture or the initial non-phasing compound is dissolved in a suitable solvent; during the dissolution of the initial non-racemic mixture in the primary coolant and/or before the presence of the solvate In the initial non-racemic mixing during and/or prior to dissolution in the solvent. 13. According to the method of claim 1 of the patent application, the initial non-racemic temperature is 1 Μ - /, the middle system will be 5 hai The 铋# 匕 物 物 铋 与 与 与 与 与 与 与 与 与 与 与 与 与 与 与 与 与 与 与 与 与 与 与 与 与 与 与 与 优先 优先 优先 优先 优先 优先 优先 优先 优先 优先 优先 优先 优先 优先 优先 优先 优先 优先The remainder of the acid addition salt. 14. The method according to the scope of claim i of the patent application, acid addition salt system fly # A a T RS - ^ 'V becomes a residue having an acid moiety containing an acid. According to the method of claim 13, wherein the acid hydrazine is present in the solvent before the initial non-racemic mixture is mixed with the solvent; X' • with the solvent and the starting non-racemic mixture Mix together; and/or • after the initial non-racemic mixture is mixed with the solvent The solvent is mixed; and/or Θ is present in the initial non-racemic mixture during and/or prior to mixing with the solvent. The method of claim 14, wherein the starting non-racemic mixture is Mixing with a solvent selected from the group consisting of toluene, ethyl acetate, diethyl ether, THF, water, alcohols, acetonitrile, ketones, and mixtures thereof. 17) The method according to the scope of the application, wherein the residue / The formation of the precipitate uses an acid selected from the group consisting of HC1, HBr, H2SO4, p-toluenesulfonic acid, methanesulfonic acid, acetic acid, and oxalic acid. 1 8 The method according to claim 17, wherein the acid is selected from the group consisting of HC1, HBr and oxalic acid. The method of claim 1, wherein the residue/precipitate is formed using an acid pair of G2_1q moles; each mole S- and R-di included in the mixture Alcohol. [20] The method of claim i, wherein the residue/^ is formed using 〇.3-4.0 moles of acid per residue/precipitate included per mole of RS_diol. • μ诹 prefers patents 沉澱物失s 。 …呈、、·口日日形式之RS-二元醇自由驗 40 1331605 22·根據申請專利範圍第1項之方法,其中該剩餘物/ 沉澱物為RS-二元醇自由鹼且該起始非消旋混合物是在選 自下列的冷劑巾:烷類,芳族烴類’極性溶劑,醇類 類及彼等的混合物。 23.根據申請專利範圍第i項之方法,其中在從最後溶 液相離析出S-二元醇或R•二元醇自由鹼或其酸加成鹽之前 對最後溶液相按照在步驟你Η)施以—或多次進一步純化 〇 “ 24,據申請專利範圍第丄項之方法,其中係經由溶劑 蒸發從最後溶液相離析出s_二元醇或R_二元醇自由盆 酸加成鹽。 ' 、25.根據中請專利範圍第1項之方法,其中該最後溶液 相為酸性,且係經由鹼化該最後溶液相,帛著相分離或經 由使用溶劑萃取接著蒸發溶劑,而從最後溶液相離析出S_ &quot;&quot;醇或R —元醇自由驗或酸加成鹽。 26.根據申請專利範圍第i項之方法,其中係經由沉殿 出R-或S - ^ 二/=兀醇自由鹼或其酸加成鹽而從最後溶液相離析 S-—7L醇或尺_二元醇自由鹼及/或酸加成鹽。 …27·根據中請專利範圍第i項之方法,其中所得該5_二 7ti Sj- X&gt; _ _ γ 70醇自由鹼或其酸加成鹽含有少量之相異鏡像 吳構物。 28.—種製備西普蘭自由驗或其酸加成鹽及㈤s·西普 :法由:或其酸加成鹽* R·西普藺自由鹼或其酸加成鹽之 ',/、包括根據申請專利範圍第ί項所述方法,接著和 1331605 以閉環。 29. 根據申請專利範圍第6項之方法,其中該起始非消 旋性混合物含有超過70%的3_二元醇。 30. 根據中請專利範圍第29㉟之方法,其中該起始非 消旋性混合物含有超過9〇%的8_二元醇。 &gt; 31.根據申請專利範圍第7項之方法,其中該起始非消 旋性混合物含有超過7〇%的汉_二元醇。The precipitate lost s. The method of claim 1, wherein the residue/precipitate is an RS-glycol free base and the initiation is in accordance with the method of claim 1, wherein the residue/precipitate is RS-diol free base. The non-racemic mixture is a cold towel selected from the group consisting of alkanes, aromatic hydrocarbons, polar solvents, alcohols, and mixtures thereof. 23. The method of claim i, wherein the final solution phase is followed in the step before the S-diol or R•diol free base or its acid addition salt is separated from the final solution. </ RTI> </ RTI> <RTIgt; </ RTI> <RTIgt; </ RTI> <RTIgt; </ RTI> <RTIgt; </ RTI> <RTIgt; </ RTI> <RTIgt; The method of claim 1, wherein the final solution phase is acidic, and by alkalizing the final solution phase, by phase separation or by solvent extraction followed by evaporation of the solvent, from the end The solution phase separates S_ &quot;&quot; alcohol or R-alcohol free test or acid addition salt. 26. According to the method of claim i, wherein R- or S - ^ two /= a sterol free base or an acid addition salt thereof to phase out the S--7L alcohol or a diol-diol free base and/or an acid addition salt from the final solution. 2727. According to the method of the patent scope i Wherein the 5_2 7ti Sj-X&gt; _ _ γ 70 alcohol free base or its acid addition salt is obtained There are a small number of different mirrored Wu constructs. 28. - Preparation of citrin free test or its acid addition salt and (5) s · Xipu: method by: or its acid addition salt * R · Xipu 蔺 free base or its The acid addition salt of ', /, includes the method according to the scope of the patent application, and then the closed loop of 1331605. 29. The method according to claim 6, wherein the initial non-racemic mixture contains more than 70% of a 3-diol. 30. The method of claim 2935, wherein the starting non-racemic mixture contains more than 9% by weight of 8-diol. &gt; 31. According to the scope of application The method of item 7, wherein the starting non-racemic mixture contains more than 7% by weight of a hanol. ^32.根據申請專利範圍第31項之方法,其中該起始非 消旋性混合物含有超過90%的R_二元醇。 33·根據申請專利範圍第 /沉殿物之RS-二元醇中的 05 : 1.5 ^ 0.9 : 1.1 &gt; 〇 95 : 或 1 · 1 〇 8項之方法,其中在該剩餘物 二元醇:S-二元醇之比例為 1·05、〇·99 : 1.01、0.98 : 1.02 登34.根據申請專利範圍第16項之方法,其中該溶劑係 k自異丙醇、丙酮、甲基異丁基酮及彼等的混合物。 Rs•乂.根據申請專利範圍帛18項之方法,其中形成該 ·—凡醇的氫溴酸鹽、鹽酸鹽或草酸鹽。 ^根據中請專利範㈣19項之其中該剩餘物/ 莫^的形成使用選自下列量的酸:〇 2 〇 4莫耳、〇 4_〇 6 所包括的每—莫耳S-和R-二元醇 所勺/9-1.1莫耳及^2.2莫耳對起始非消旋混合物中 7·根據中請專利範圍帛2G項之方法,其中該剩餘物/ 莫^的形成使用選自下列量的酸0.4-0.6莫耳、0 9-u 及1.8-2.2莫耳的酸對剩餘物/沉澱物中所包括的每— 42 1331605 莫耳RS-二元醇。 38. 根據申請專利範圍第22項之方法,其中該溶劑係 選自:庚烷、己烷、甲苯、苯、二甲苯、乙腈、甲醇、異 丙醇、甲基異丁基酮及彼等的混合物。 39. 根據申請專利範圍第26項之方法,其中R-二元醇 或S-二元醇酸加成鹽係以磷酸鹽或草酸鹽形式沉澱出。 40. 根據申請專利範圍第27項之方法,其中所得該S-二元醇或R-二元醇自由鹼或其酸加成鹽含有少於3%之相 異鏡像異構物。 4 1,根據申請專利範圍第40項之方法,其中所得該S-二元醇或R-二元醇自由鹼或其酸加成鹽含有少於2%之相 異鏡像異構物。 42.根據申請專利範圍第4 1項之方法,其中所得該S-二元醇或R-二元醇自由鹼或其酸加成鹽含有少於1%之相 異鏡像異構物。The method of claim 31, wherein the starting non-racemic mixture contains more than 90% of the R-diol. 33. According to the scope of application for patents / Shen Dian in RS-diols 05 : 1.5 ^ 0.9 : 1.1 &gt; 〇 95 : or 1 · 1 〇 8 of the method, in which the residue diol: The ratio of S-diol is 1.05, 〇·99: 1.01, 0.98: 1.02. 34. According to the method of claim 16, wherein the solvent is k from isopropanol, acetone, methyl isobutyl A mixture of ketones and theirs. Rs•乂. According to the method of claim 18, wherein the hydrobromide, hydrochloride or oxalate of the alcohol is formed. ^According to the formation of the remainder/mouse in the 19th item of the patent application (4), an acid selected from the group consisting of 〇2 〇4 耳, 〇4_〇6, including each of the Mo-S- and R- The diol is scooped by /9-1.1 moles and ^2.2 moles in the starting non-racemic mixture. 7. The method according to the scope of the patent application 帛 2G, wherein the formation of the residue / mole is selected from the following The amount of acid 0.4-0.6 moles, 0 9-u and 1.8-2.2 moles of acid per residue contained in the residue/precipitate was 42 1331605 moles of RS-diol. 38. The method of claim 22, wherein the solvent is selected from the group consisting of heptane, hexane, toluene, benzene, xylene, acetonitrile, methanol, isopropanol, methyl isobutyl ketone, and the like. mixture. 39. The method of claim 26, wherein the R-glycol or S-glycolic acid addition salt is precipitated as a phosphate or oxalate salt. 40. The method according to claim 27, wherein the S-diol or R-diol free base or an acid addition salt thereof obtained contains less than 3% of a mirror image isomer. The method of claim 40, wherein the S-glycol or R-diol free base or an acid addition salt thereof contains less than 2% of a mirror image isomer. 42. The method of claim 41, wherein the S-diol or R-diol free base or acid addition salt thereof is obtained containing less than 1% of a mirror image isomer. 拾壹、圖式: 無0 43Pick up, pattern: no 0 43
TW092135925A 2002-12-23 2003-12-18 A process for the preparation of racemic citalopram diol and/or s- or r-citalopram diols and the use of such diols for the preparation of racemic citalopram, r-citalopram and/or s-citalopram TWI331605B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200202004 2002-12-23

Publications (2)

Publication Number Publication Date
TW200512202A TW200512202A (en) 2005-04-01
TWI331605B true TWI331605B (en) 2010-10-11

Family

ID=35423357

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092135925A TWI331605B (en) 2002-12-23 2003-12-18 A process for the preparation of racemic citalopram diol and/or s- or r-citalopram diols and the use of such diols for the preparation of racemic citalopram, r-citalopram and/or s-citalopram

Country Status (17)

Country Link
KR (1) KR101076640B1 (en)
CN (1) CN100334071C (en)
AR (1) AR042655A1 (en)
BR (1) BR0317629A (en)
DK (1) DK1581483T3 (en)
EA (1) EA009061B1 (en)
ES (1) ES2385975T3 (en)
ME (1) MEP5708A (en)
MY (1) MY142404A (en)
PE (1) PE20050065A1 (en)
PT (1) PT1581483E (en)
RS (1) RS52152B (en)
SI (1) SI1581483T1 (en)
TW (1) TWI331605B (en)
UA (1) UA84859C2 (en)
UY (1) UY28146A1 (en)
ZA (1) ZA200504715B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA95199U (en) 2014-07-09 2014-12-10 PRECISION DISPOSER WITH ACCURATE DOSAGE FOR Bulk Products
CN110590602B (en) * 2019-09-25 2022-04-05 浙江海森药业股份有限公司 Resolution refining method of racemic citalopram diol
CN114763329A (en) * 2021-01-14 2022-07-19 浙江华海药业股份有限公司 Method for purifying citalopram key intermediate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
AR034612A1 (en) * 2001-06-25 2004-03-03 Lundbeck & Co As H PROCESS FOR THE PREPARATION OF RACEMIC CITALOPRAM AND / OR OF THE S- OR R-CITALOPRAM THROUGH THE SEPARATION OF A MIXING OF R- AND S-CITALOPRAM

Also Published As

Publication number Publication date
RS20050488A (en) 2007-06-04
CN100334071C (en) 2007-08-29
KR101076640B1 (en) 2011-10-27
ZA200504715B (en) 2006-08-30
EA009061B1 (en) 2007-10-26
CN1729164A (en) 2006-02-01
DK1581483T3 (en) 2012-07-23
SI1581483T1 (en) 2012-09-28
PE20050065A1 (en) 2005-02-18
AR042655A1 (en) 2005-06-29
RS52152B (en) 2012-08-31
BR0317629A (en) 2005-11-29
UA84859C2 (en) 2008-12-10
PT1581483E (en) 2012-07-24
KR20050093801A (en) 2005-09-23
UY28146A1 (en) 2004-07-30
ES2385975T3 (en) 2012-08-06
EA200501042A1 (en) 2005-12-29
ME00034B (en) 2010-02-10
TW200512202A (en) 2005-04-01
MEP5708A (en) 2010-02-10
MY142404A (en) 2010-11-30

Similar Documents

Publication Publication Date Title
CN101622225B (en) Methods for isolating propargylated aminoindans
TWI236473B (en) Process for the preparation of racemic citalopram and/or S-or R-citalopram by separation of a mixture of R-and S-citalopram
FR2900655A1 (en) ALPHA FORM OF IMATINIB MESYLATE AND PROCESS FOR PRODUCTION THEREOF
CN104379559A (en) Novel compounds
TW200951102A (en) Resolving of 4,5-dimethoxy-1-(methylaminomethyl)-benzocyclobutane
JP4505335B2 (en) A process for producing racemic citalopramdiol and / or S- or R-citalopramdiol, and a process for using said diol to produce racemic citalopram, R-citalopram and / or S-citalopram.
TWI331605B (en) A process for the preparation of racemic citalopram diol and/or s- or r-citalopram diols and the use of such diols for the preparation of racemic citalopram, r-citalopram and/or s-citalopram
CH641181A5 (en) INDOLO-QUINOLIZIDINES, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC COMPOSITIONS CONTAINING THEM.
CN101580482A (en) Method for preparing rivastigmine hydrogen tartrate and application thereof
WO2000032554A1 (en) Process for the resolution of tramadol
CN101389621A (en) Method for preparing (S) - (-) -N, N-dimethyl-3- (2-thienyl) -3-hydroxypropyl amine serving as intermediate of duloxetine
US20070117992A1 (en) Crystalline citalopram diol intermediate alkali
ES2210128T3 (en) DERIVATIVES OF (2S) -AMINOINDANO, PROCEDURE FOR ITS PREPARATION AND ITS USE AS A DOPAMINE SELECTIVE BINDING D3.
EP2513042A2 (en) Solid dapoxetine
CN101883486A (en) Method for preparing R-gossypol L-phenylalaninol dienamine
TWI332939B (en) Toremifene crystallization method
CN1046281C (en) Pharmacologically active enantiomers and methods for their preparation
JP2008521804A (en) Method for crystallizing benzphetamine
WO2003002510A1 (en) Crystalline form of a phenylethanolamine, the preparation thereof and pharmaceutical compositions comprising the same
CN119390591A (en) A method for purifying rivastigmine intermediate
JP2002533457A (en) Method for producing paroxetine acetate or paroxetine analog
JP2002533441A (en) Process for producing paroxetine acetate and its analogs

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees